

5th European Conference on Schizophrenia Research (ECSR)

Bridging Gaps – Improving Outcomes

organized by the European Scientific Association on
Schizophrenia and other Psychoses (ESAS)

24 – 26 September 2015
Berlin, Germany

Final Programme

The European Accreditation Committee in CNS (EACIC) has
granted 22 CME credits to this congress.



The ECSR is organized in cooperation with the

World Psychiatric Association (WPA)
and its Section on Schizophrenia



German Association for Psychiatry,
Psychotherapy and Psychosomatics (DGPPN)



European Psychiatric Association (EPA)
and its Section on Schizophrenia



Competence Network
on Schizophrenia (CNS)



TABLE OF CONTENT

	Page
Welcome Address.....	3
Conference Organisation.....	4
Format Descriptions / CME Credits.....	5
Opening Ceremony and Networking Reception.....	6
Overview Scientific Programme.....	7
Scientific Programme	
Thursday, 24 September.....	10
Friday, 25 September.....	23
Saturday, 26 September.....	40
Conference Information.....	52
Floorplan	56
Acknowledgements / Fundings.....	57
Poster Areas.....	58
Index Chairpersons, Authors and Presenters.....	59
Notes	62



Dear Colleagues,

According to a recent systematic analysis for the Global Burden of Disease of the World Health Organization (WHO) schizophrenia ranks globally on 11th position among the top 25 causes of global Years Lived with Disability (YLDs) in 2013. Despite advances in pharmacological and psychosocial therapies a large portion of individuals with schizophrenia who require treatment do not receive adequate treatment if any, even in countries with a well-organized health care system. Kohn et al. (2004) identified a treatment gap for mental disorders of more than 50% in Western Europe, for schizophrenia and other psychotic disorders the respective gap was found to be 32,2% worldwide and 17,8% in Western Europe. Reasons

range from misallocation of resources, to lacking availability of essential services and/or therapies, missing or not applying guidelines reflecting current state of the art, or "simply" not meeting patients' needs.

In addition to this treatment gap we are confronted with numerous knowledge-gaps, e.g. about the nature and causes of the disorder. We all are aware that schizophrenia is not a single, uniform entity. It is a broad clinical syndrome which is characterised by heterogeneity of its genetic underpinnings, neurodevelopmental trajectories and marked variation in its course and outcome. Further there is also a knowledge gap with regard to effective therapies for certain features of schizophrenia like negative symptoms and cognitive impairments.

Due to this situation it is obvious that there is a need for concerted research efforts to narrow down the „knowledge gap“ and for proactive measures on international scale to close the „treatment gap“. This challenging task is reflected in the motto of the ECSR 2015: "Bridging gaps – improving outcomes."

According to the congress-motto the scientific programme of the 5th ECSR provides a comprehensive overview on recent research projects and developments in schizophrenia treatment. Acknowledged experts, young scientists, and clinicians address different facets of gaps – gaps in mental health policy and financing (availability) but also issues described as utilisation gap (acceptability of care), science-to-service gap (translational gap), or efficacy-effectiveness gap as well as strategies to overcome non-adherence ("pre-scribing-taking gap") just to mention some – in high quality contributions in terms of plenary lectures, pro-con-debates, symposia, oral presentations and poster sessions.

On behalf of the Scientific Committee and the organisers, I cordially welcome you at the 5th European Schizophrenia Research Conference and thank you for your attendance.

Sincerely yours,



Wolfgang Gaebel
Congress President and President of ESAS

CONFERENCE ORGANISATION

SCIENTIFIC ORGANISER



www.esasnet.eu

SCIENTIFIC SECRETARIAT

Wolfgang Gaebel, Wolfgang Wölwer,
Viktoria Toeller
c/o Department of Psychiatry and Psychotherapy
Heinrich-Heine-University Düsseldorf

The ECSR is organised in cooperation with the



World Psychiatric Association
(WPA) and its Section
on Schizophrenia



Competence Network on
Schizophrenia (CNS) and
its supporting association
PsychoseNetz e.V.



German Association for
Psychiatry, Psychotherapy
and Psychosomatics (DGPPN)



European Psychiatric
Association (EPA) and its
Section on Schizophrenia

PROFESSIONAL CONFERENCE ORGANISER



Hanser & Co GmbH
Postfach 12 21
22882 Barsbüttel, Germany
Phone: +49-40-670 88 20
Fax: +49-40-670 32 83
Email: schizophrenia@cpo-hanser.de

SCIENTIFIC PROGRAMME COMMITTEE

Wolfgang Gaebel, Germany
Silvana Galderisi, Italy
Joachim Klosterkötter, Germany
Wolfgang Maier, Germany
Hans-Jürgen Möller, Germany
Wulf Rössler, Switzerland
Werner Strik, Switzerland
Wolfgang Wölwer, Germany

ADVISORY PROGRAMME COMMITTEE

George Awad, Canada
Dinesh Bhugra, UK
Gerd Buchkremer, Germany
George Christodoulou, Greece
Peter Falkai, Germany
Wagner F. Gattaz, Brazil
Birte Glenthøj, Denmark
Philippe Gorwood, France
Heinz Häfner, Germany
Cyril Höschl, Czech Republic
Valery Krasnov, Russia
Shôn Lewis, UK
Jan Libiger, Czech Republic
Mario Maj, Italy
Stephen Marder, USA
Patrick McGorry, Australia
Andreas Meyer-Lindenberg, Germany
Merete Nordentoft, Denmark
Michael Owen, UK
Victor Peralta, Spain
Pedro Ruiz, USA
Bernard Sabbe, Belgium
Norman Sartorius, Switzerland
Frank Schneider, Germany

The scientific programme will comprise the following formats:

PLENARY LECTURES

Invited lectures of 45 min each, covering current hotspots in schizophrenia research and given by leading European and international experts.

SYMPOSIA

Pre-arranged or submitted symposia of 90 min each, including four presentations and 15 min time for discussion covering major topics of the conference. Both symposia with a clear scientific focus and those with a clear clinical focus will be included.

PRO AND CON DEBATES

During the daily 90-minutes debates current controversial issues will be introduced and discussed. One moderator and two discussants (pro and con) will raise interactive and lively debates.

ORAL PRESENTATION SESSIONS

Submitted presentations grouped by topics into thematic oral sessions of 90 min, including six papers each.

POSTER SESSIONS

Submitted abstracts were grouped by topics into thematic sessions of poster board presentations in guided tours.

CME ACCREDITATION

The European Accreditation Committee in CNS (EACIC) has granted **22 CME credits** to this congress. Participants requesting CME credits are required to complete the online evaluation form on the EACIC website www.eacic.eu.



Please follow the below steps to receive your CME certificate.

1. Go to the EACIC website www.eacic.eu
2. Click on the CME logo (in the blue bar on the right hand side of the webpage)
3. Choose the option "I am already registered" or "I am not registered"
4. Log on or register
5. Choose the option 1 "I want to evaluate an accredited event"
6. Choose the event for which you would like to receive CME credits
7. Complete the online evaluation form
8. Press "save"
9. Your CME certificate will be automatically emailed to the address provided

The deadline to complete the evaluation form is **26 November 2015**.

European Accreditation Committee
in CNS (EACIC)

47, avenue Jacques Pastur
1180 Brussels, Belgium
www.eacic.eu

OPENING AND NETWORKING RECEPTION

THURSDAY, 24 SEPTEMBER 2015

Opening Ceremony

09:15 – 10:30

Cambridge, 2nd Floor

► Presidential Address

Professor Wolfgang Gaebel, Düsseldorf, Germany
Congress President, President of the European Scientific Association
on Schizophrenia and other Psychoses
Bridging gaps – improving outcomes

► Aretaeus-Award Ceremony – Laureate 2015

Networking Reception

18:00 – 20:00

Foyer, Ground Floor

At the end of the scientific sessions participants are invited to join the Networking Reception for informal conversation with colleagues in the Foyer of the Dahlem Cube. Finger food and drinks will be provided.



Room Time	Cambridge 2nd Floor	Oxford 2nd Floor	Harvard 1st Floor	Stanford 1st Floor	Princeton 1st Floor	Foyer Ground floor
09:30 – 10:15	Opening Ceremony					Registration Counter Opening Hours: 08:00 – 18:00
10:15 – 11:00	PL-01 An integrated sociodevelop- mental-cognitive model of schizo- phrenia	Broadcasting of Plenary P-01 in room Oxford				
	Coffee Break					
11:30 – 13:00	S-01 Interventions in people at high risk of psychosis: new results of intervention trials	S-02 Models for un- derstanding nega- tive symptoms	S-03 What happens in adolescence? Developmental aspects in devel- oping psychosis	S-04 Structural and functional effects of ECT in patients with schizophren- ic and affective psychoses	S-05 Novel technolo- gies to investigate motor behavior in psychiatric disorders	
13:00 – 14:30	Lunch Break 13:30 – 14:30 ▶ Guided Poster Sessions ⊕ Event Area, Ground Floor: P-02, P-04, P-05 ⊕ Foyer, 2nd Floor: P-01 ⊕ Sorbonne 2, 2nd Floor: P-03					
14:30 – 16:00	D-01 Early medication discontinuation in first-episode schizophrenia – beneficial or risky?	S-06 The single symp- tom approach: understanding and treating auditory verbal hallucinations and formal thought disorders	S-07 Patient perspec- tives, quality of life and affective symptoms in the early treated course of psy- chotic disorders	S-08 Multimodal imaging of the psychosis high-risk state	O-02 Neuroimaging	
	Coffee Break					
16:30 – 18:00	S-09 New findings about what dopa- mine does in the prefrontal cortex: relevance to schizophrenia	S-10 Autoimmune encephalitis and mild encephalitis – from epidemi- ology to clinic	S-11 Social cognition in schizophrenia and beyond	S-12 Predictive cod- ing and sensory disturbances in schizophrenia: from mice to men	O-01 Early detection and intervention	
18:00 – 20:00	Networking Reception Foyer Area, Ground Floor					

PL-Plenary Lecture

D-Debate

S-Symposium

O-Oral Presentation

P-Poster

Room Time	Cambridge 2nd Floor	Oxford 2nd Floor	Harvard 1st Floor	Stanford 1st Floor	Princeton 1st Floor	Foyer Ground floor
08:30 – 10:00	S-13 Neuroimaging approaches to understanding negative symptoms	S-14 Modulating neural plasticity for the treatment of schizophrenia	S-15 Depressive episodes in the course of schizophrenia-spectrum disorders: clinical challenges, therapeutic strategies	S-16 Clozapine: the art of prescribing	S-17 Bridging animal-human NMDAR models of schizophrenia through EEG biomarkers in behaving rodents and humans	Registration Counter Opening Hours: 08:00 – 18:30
	Coffee Break					
10:30 – 12:00	S-18 Impact of negative symptoms on schizophrenia functional outcome	S-19 Verbal and non-verbal communication deficits in schizophrenia	S-20 Psychological treatments for posttraumatic stress disorder in psychosis: feasibility, safety and efficacy	D-02 Should "schizophrenia" be renamed?	S-21 Neuroinflammation and infection in schizophrenia	
12:15 – 13:00	PL-02 Perspectives of drug development for the treatment of schizophrenia	Broadcasting of Plenary P-02 in room Oxford				
13:00 – 14:30	Lunch Break 13:30 – 14:30 ► Guided Poster Sessions ➤ Event Area, Ground Floor: P-06, P-09, P-10 ➤ Foyer, 2nd Floor: P-07 ➤ Sorbonne 2, 2nd Floor: P-08					
14:30 – 16:00	S-22 Symptom dimensions and their clinical implication in schizophrenia	S-23 Lifespan development of schizophrenia and how the treatments improve it	S-24 Improving outcomes: factors influencing help seeking behavior, duration of untreated psychosis and treatment outcome...	S-25 Detecting psychosis proneness: schizotypy and clinical high risk	S-26 Disturbed connectivity in schizophrenia: from dysfunctional white matter tracts to molecular findings	
	Coffee Break					
16:30 – 18:00	S-27 The role of psychotherapy in the treatment of schizophrenia	S-28 Assessment of negative symptoms: challenges and recent developments	S-29 Paranoia as a symptom dimension in schizophrenia	S-30 Predicting Psychosis – Methodological concepts and first findings of the 'PRONIA' project	O-03 Drug treatment	
	Break					
18:15 – 19:45		S-31 Avolition and asociality: bridging gaps between animal and human research	S-32 Social cognition in schizophrenia – new task developments and establishing paradigms	S-33 Schizophrenia as neurodevelopmental disorder and effects of antipsychotic treatment: new insights from animal models	O-04 Comorbidity	

Room Time	Cambridge 2nd Floor	Oxford 2nd Floor	Harvard 1st Floor	Stanford 1st Floor	Princeton 1st Floor	Foyer Ground floor
08:30 – 10:00	S-34 Gaps in knowledge around and implementation of early intervention for psychosis: setting an agenda for the future	S-35 Clinical and biological impact of exercise interventions in schizophrenia	O-05 Alternative treatment approaches	S-37 The neurobiology of language related symptoms in schizophrenia	S-38 Computational approaches to schizophrenia	Registration Counter Opening Hours: 08:00 – 16:00
	Coffee Break					
10:30 – 12:00	S-39 Epidemiological and clinical aspects of psychosis risk syndromes and psychotic experiences in children, adolescents and adults	S-40 Current state and perspectives of policies for schizophrenia care	S-41 Evidence for brain stimulation methods in schizophrenia	S-42 Dopamine and learning dysfunction in schizophrenia	O-06 Psychosocial treatment	
12:15 – 13:00	PL-03 Predictors and mechanisms of conversion to psychosis	Broadcasting of Plenary P-03 in room Oxford				
13:00 – 14:30	Lunch Break 13:30 – 14:30 ► Guided Poster Sessions 📍 Event Area, Ground Floor: P-12, P-14, P-15 📍 Foyer, 2nd Floor: P-11 📍 Sorbonne 2, 2nd Floor: P-13					
14:30 – 16:00		S-43 Cycloid psychoses and chronic schizophrenia: clinical profiles and the role of CNVs	S-44 Bridging the gap between treatment engagement and treatment outcomes	S-45 Abnormalities of motor function in neuropsychiatric disorders: a transdiagnostic approach	O-07 Neuropsychology	

PL-Plenary Lecture

D-Debate

S-Symposium

O-Oral Presentation

P-Poster

PL-01	PLENARY LECTURES
10:15 – 11:00	B Cambridge, 2nd Floor
An integrated sociodevelopmental-cognitive model of schizophrenia	
Chair: <i>W. Gaebel, Düsseldorf, Germany</i>	

PL-01-001

An integrated sociodevelopmental-cognitive model of schizophrenia

O. Howes, London, United Kingdom

B Broadcasting of Plenary Lecture in room Oxford

S-01	SYMPOSIA
11:30 – 13:00	Cambridge, 2nd Floor
Interventions in people at high risk of psychosis: new results of intervention trials	
Chairs: <i>A. Bechdolf, Berlin, Germany</i> <i>M. van der Gaag, Oegstgeest, The Netherlands</i>	

S-01-001

A randomised controlled trial of CBT for young people at risk for psychosis: the Detection and Evaluation of Psychological Therapy (DEPT_H) trial

H. J. Stain, Durham, United Kingdom

S. Bucci, A. Baker, V. Carr, R. Emsley, S. Halpin, T. Lewin, U. Schall, V. Clarke, K. Crittenden, M. Startup

S-01-002

Cost-effectiveness of preventing psychosis in the Dutch Early Detection and Intervention Evaluation trial (EDIE-NL) and the profiling of ultrahigh risk patients into risk classes

H. K. Ising, The Hague, The Netherlands

F. Smit, S. Ruhrmann, W. Veling, J. Rietdijk, S. Dragt, R. Klaassen, N. Savelsberg, N. Burger, N. Boonstra, D. Nleman, D. Linszen, L. Wunderink, M. van der Gaag

S-01-003

The four-year follow-up of the EDIE-NL trial

M. van der Gaag, Oegstgeest, The Netherlands

H. K. Ising, N. S. P. Savelsberg, N. A. F. M. Burger, M. Willebrands-Mendrik, J. Rietdijk, S. Dragt, R. M. C. Klaassen, N. Boonstra, D. H. Nieman, D. H. Linszen, L. Wunderink

S-01-004

Predictors of treatment response to psychosocial interventions in people at risk

A. Bechdolf, Berlin, Germany

H. Wessels, M. Wagner, K. Kuhr, J. Berning, V. Pützfeld, B. Janssen, R. Bottlender, K. Maurer, H.-J. Möller, W. Gaebel, H. Häfner, W. Maier, J. Klosterkötter

S-02	SYMPOSIA
11:30 – 13:00	Oxford, 2nd Floor
Models for understanding negative symptoms	
<i>Chairs: S. Kaiser, Zurich, Switzerland</i>	
<i>T. Lincoln, Hamburg, Germany</i>	

S-02-001

Effect of different models on negative symptom prevalence

J. P. Lyne, Dublin, Ireland

M. Clarke

S-02-002

What impairs social interaction in patients with negative symptoms? Interpersonal consequences of blunted facial expressiveness

M. Riehle, Hamburg, Germany

T. M. Lincoln

S-02-003

Negative symptoms as dysfunctional decision-making

S. Kaiser, Zurich, Switzerland

S-02-004

Neurobiological correlates of reward learning and cognitive deficits – relevance for negative symptoms

F. Schlagenhauf, Berlin, Germany

S-03	SYMPOSIA
11:30 – 13:00	Harvard, 1st Floor
What happens in adolescence? Developmental aspects in developing psychosis	
<i>Chairs: F. Schultze-Lutter, Bern, Switzerland</i>	
<i>P. Uhlhaas, Glasgow, United Kingdom</i>	

S-03-001

Impact of age on the prevalence and clinical significance of risk symptoms in 8- to 40-year-olds of the general population

F. Schultze-Lutter, Bern, Switzerland

C. Michel, B. G. Schimmelmann

S-03-002

Adolescent brain development and the onset of psychosis

S. Wood, Birmingham, United Kingdom

S-03-003

Development of neural oscillations during adolescence: relevance of the development and early detection of psychosis?

P. Uhlhaas, Glasgow, United Kingdom

S-03-004

Developing psychosis: a mentalization-based perspective

M. Debbané, Geneva, Switzerland

S-04	SYMPOSIA
11:30 – 13:00	Stanford, 1st Floor
Structural and functional effects of ECT in patients with schizophrenic and affective psychoses	
<i>Chairs: C. Wolf, Homburg, Germany</i>	
<i>P. Thomann, Heidelberg, Germany</i>	

S-04-001

Effects of ECT on cerebral blood flow and metabolism: a focus on invasive neuroimaging techniques

M. Depping, Heidelberg, Germany

S-04-002

ECT-related effects on brain volume in patients with schizophrenia

P. Thomann, Heidelberg, Germany

R. C. Wolf, H. Nolte, D. Hirjak, S. Hofer, M. Depping, U. Seidl, B. Stieltjes, K. Maier-Hein, T. Wüstenberg

S-04-003

Does ECT modulate specific brain regions or neural systems?

C. Wolf, Homburg, Germany

S-04-004

ECT-related effects on brain resting-state functional connectivity in patients with schizophrenia

T. Wüstenberg, Berlin, Germany

R. C. Wolf, H. M. Nolte, P. A. Thomann

S-05	SYMPOSIA
11:30 – 13:00	Princeton, 1st Floor
Novel technologies to investigate motor behavior in psychiatric disorders	
<i>Chairs: P. van Harten, Maastricht, The Netherlands</i>	
<i>S. Walther, Bern, Switzerland</i>	

S-05-001

Novel instrumental devices measuring movement disorders in psychiatry

P. van Harten, Maastricht, The Netherlands

T. Mentzel, R. Lieveise, H. Daanen

S-05-002

Video-based quantification of body movement indicates negative symptoms – a replication

Z. Kupper, Bern, Switzerland

F. Ramseyer, M. Drozynski, H. Hoffmann, W. Tschacher

S-05-003

Association between instrumental measurements of dyskinesia and schizotypy in subjects with auditory verbal hallucinations and healthy controls

A. Willems, Amersfoort, The Netherlands

I. Sommer, D. Tenback, J. Koning, P. van Harten

S-05-004

Actigraphy movement patterns indicate psychopathological dimensions in schizophrenia

S. Walther, Bern, Switzerland

P-01	POSTER SESSIONS
13:30 – 14:30	Foyer, 2nd Floor
Epidemiology and health services research	
Chair: I. Melle, Oslo, Norway	

P-01-001

Ageing in schizophrenia: a systematic review

M. Isohanni, Oulu, Finland

I. Isohanni

P-01-002

Prevalence of clinical high risk states of psychosis in the Swiss general population between 16 and 40 years

C. Michel, Bern, Switzerland

B. G. Schimmelmann, F. Schultze-Lutter

P-01-003

The financial crisis in Greece and the impact on psychiatric patients

E. Neroutsos, Magoula Elefsina, Greece

M. Fiste, S. Foteli, E. Kontomina, E. Bisbiki, A. Zachariadis

P-01-004

Prevalence, employment rate and cost of schizophrenia in a high income welfare society: a population-based study using comprehensive welfare and healthcare registers

S. Evensen, Oslo, Norway

T. Wisløff, H. Bull, J. Lystad, T. Ueland, E. Falkum

P-01-005

High school dropout rate in patients with schizophrenia spectrum disorders

E. Ullevoldsæter, Oslo, Norway

M. Aas, I. Melle

P-01-006

The Moray psychosis survey: prevalence, demographics and treatment characteristics in a rural cohort of patients diagnosed with schizophrenia

A. Macbeth, Edinburgh, United Kingdom

H. Greaves, T. Hacker

P-01-007

Why using gender-sensitive methods in schizophrenia research is vital

A. Levinsson, Gothenburg, Sweden

P-01-008

Day-hospital: comprehensive treatment for psychosis

L. Mata Iturralde, Madrid, Spain

L. Rodriguez Blanco, A. Vian, R. Álvarez, S. Ovejero,

M. Iza, S. Sánchez, L. Muñoz Lorenzo

P-01-009

Factors related to long-term hospitalization of patients with chronic schizophrenia in Korea

Y. Chung, Yangsan, Republic of Korea

O.-J. Jang, B.-D. Lee

P-01-010

Risk factors for tremor in a population of patients with severe mental illness: an 18-year prospective study in a geographically representative sample The Curacao Extrapyramidal Syndromes study XI

C. Mentzel, Amersfoort, The Netherlands

R. Bakker, J. van Os, M. Drukker, M. van den Oever,

G. Matroos, H. Hoek, M. Tijssen, P. van Harten

P-01-011

Prevalence and clinical differences between cannabis and non-cannabis users in a sample of subjects at risk for developing psychosis

M. Pardo Gallego, Barcelona, Spain

J. Tor, D. Muñoz, M. Rodriguez, E. De la Serna, G. Sugranyes, I. Baeza, M. Dolz

P-02 POSTER SESSIONS

13:30 – 14:30 Event Area, Ground Floor

Diagnosis and classification

Chair: V. Larach, Santiago, Chile

P-02-001

Subtyping schizophrenia: a comparison of positive/negative and system-specific approaches

M. Jäger, Günzburg, Germany

L. Fabian

P-02-002

Which symptom dimensions of schizophrenia are predictors of clinical and demographic variables?

M. Bajouco, Coimbra, Portugal

A. T. Pereira, C. Roque, V. Nogueira, M. J. Soares,

J. Valente, N. Madeira, L. A. Oliveira, C. Pata, P. Michele,

A. Ferreira de Macedo

P-02-003

Insight, depression and compliance in schizophrenia

G. Hamdi, Manouba, Tunisia

H. Ben Ammar

P-02-004

How to measure negative symptoms? A review of observer-rated and self-report instruments and challenges for future research

K. Burckhardt, Hamburg, Germany

M. Engel, T. Lincoln

P-02-005

The acceptance and action scale for delusions: development and preliminary results

M. J. Martins, Coimbra, Portugal

P. Castilho, C. Carvalho, A. T. Pereira, A. Macedo

P-02-006

The Bern Psychopathology Scale: comparison of symptom dimensions in patients with schizophrenia and major depressive disorder

S. Steinau, Bern, Switzerland

K. Stegmayer, H. Horn, N. Razavi, W. Strik, S. Walther

P-02-007

Can basic symptoms be reliably assessed in a self-rating questionnaire?

C. Michel, Bern, Switzerland

B. G. Schimmelmann, F. Schultze-Lutter

P-02-008

Movement disorders in psychiatry: novel instrumental devices

T. Mentzel, Amersfoort, The Netherlands

R. Lieverse, H. Daanen, P. van Harten

P-02-009

Twin brothers with a shared delusional disorder

C. Bonadio, São Paulo, Brazil

L. Campagnaro, E. Calfat, V. Otani

P-02-010

The importance of a causative underlying medical condition

E. Neroutsos, Magoula Elefsina, Greece

S. Foteli, A. Zachariadis, M. Fiste

P-02-012

Differential relationships of the two subdomains of negative symptoms in chronically ill psychotic patients

R. Bruggeman, Groningen, The Netherlands

A. Stiekema, E. Liemburg, L. van der Meer, S. Castelein,

R. Stewart, J. van Weeghel, A. Aleman

P-03 POSTER SESSIONS

13:30 – 14:30 Sorbonne 2, 2nd Floor

Drug and somatic treatment I

Chair: M. Isohanni, Oulu, Finland

P-03-001

Venous compared to capillary blood sampling with a point-of-care device in clozapine treatment: patients' preferences

*J. Bogers, Oegstgeest, The Netherlands
D. Cohen*

P-03-002

Glycopyrronium bromide for clozapine induced nocturnal drooling in patients with a psychiatric disorder: a randomized, cross-over, double-blind placebo controlled trial (QUITSPIT-study)

*P. Schulte, Alkmaar, The Netherlands
J. Colen-de Koning, W.-H. Man, I. Wilting, H. Doedeman, W. Cahn, R. Heerdink, T. Egberts, I. van Haelst*

P-03-003

Use of paliperidone in acute psychoses

*S. Ovejero Garcia, Madrid, Spain
L. Mata, R. Alvarez, M. Iza, S. Sanchez-Alonso*

P-03-004

Use of paliperidone palmitate in acute inpatients

*S. Ovejero Garcia, Madrid, Spain
M. Iza, R. Alvarez, L. Mata, S. Sanchez-Alonso*

P-03-005

Percentage of use of biperiden in clinically stable patients treated with paliperidone

*S. Sánchez Alonso, Madrid, Spain
S. Ovejero, L. Mata, R. Álvarez, M. Iza*

P-03-007

Continuation rates in patients treated with paliperidone palmitate

*S. Sánchez Alonso, Madrid, Spain
S. Ovejero, L. Mata, M. Iza, R. Álvarez*

P-03-008

Evaluation of the use of long-acting injectable antipsychotics in an inpatient psychiatric unit

*L. García González, Oviedo, Spain
C. Rodríguez Mercado, S. Bestene Medina, A. González Fernández, M. Jalón Urbina, L. Pérez Gómez*

P-03-009

Trends in the antipsychotic treatment of psychiatric outpatients

*R. Alvarez Garcia, Mostoles Madrid, Spain
L. Mata Iturralde, S. Sanchez Alonso, S. Ovejero Garcia, M. Iza Cia, L. Muñoz Lorenzo, P. Puras Rico, M. Agudo Urbanos, J. J. Carballo Belloso, E. Baca Garcia*

P-03-010

Evidence of role of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: an analysis of multi-factors predicting long-term prognosis

*H. Yamanaka, Chiba, Japan
N. Kanahara, T. Suzuki, M. Takase, T. Moriyama, H. Watanabe, T. Hirata, M. Asano, M. Iyo*

P-03-011

Glucose-6-phosphate dehydrogenase activity as a biomarker of negative metabolic outcome in schizophrenic patients after treatment with traditional antipsychotics

*M. Uzbekov, Moscow, Russia
S. Ivanova, L. Smirnova, N. Bokhan, A. Semke*

P-03-012

Social adjustment in the outpatients treated with long-acting antipsychotics

*M. C. Pirlog, Bucharest, Romania
A. L. Chirita, M. Mutica*

P-04	POSTER SESSIONS
13:30 – 14:30	Event Area, Ground Floor
Neuropsychology I	
Chair: S. Walther, Bern, Switzerland	

P-04-001

Cognitive functions in a large sample of patients with schizophrenia and first degree relatives

M. Chieffi, Naples, Italy

S. Galderisi, A. Mucci, A. Rossi, P. Rocca, A. Bertolino, M. Mai

P-04-002

Social cognition in offspring schizophrenia and bipolar disorder

C. A. Jerlang Christiani, Gentofte, Denmark

J. R. Møllegaard Jepsen, A. Thorup, N. Hemager, B. Klee Burton, D. Ellersgaard, K. S. Spang, A. Greve, O. Mors, K. Plessen, M. Nordentoft

P-04-003

Emotional intelligence in schizophrenia patients, first-degree relatives and healthy controls. A study with the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT)

À. Albacete, L'Hospitalet de Llobregat, Spain

F. Contreras, N. Custal, J. M. Menchón

P-04-004

The relationship of two social cognition concepts as measured by Thematic Apperception Test in paranoid schizophrenia

K. Hosakova, Olomouc, Czech Republic

M. Lecbych

P-04-005

Theory of mind in females with schizophrenia compared to females with borderline personality disorder

A. Vaskinn, Oslo, Norway

B. T. Antonsen, R. A. Fretland, K. Sundet, T. Wilberg

P-04-006

Counterfactual thinking is impaired in non-psychotic first-degree relatives of schizophrenia patients

À. Albacete, L'Hospitalet de Llobregat, Spain

F. Contreras Fernandez, C. Bosque, J. M. Menchón

P-04-007

Context dependent differences in learning between patients with depressive episode and schizophrenia

O. Listunova, Heidelberg, Germany

M. Bartolovic, M. Weisbrod, D. Roesch-Ely

P-04-008

Schizophrenia patients show abnormal serial position effects in a working memory visual motion task

M. Stäblein, Frankfurt am Main, Germany

L. Sieprath, C. Knöchel, A. Landertinger, C. Schmied, D. Ghinea, J. Mayer, R. Bittner, A. Reif, V. Oertel-Knöchel

P-04-009

Semantic priming in schizophrenia: the effect of associative strength

J. C. Ruiz, Valencia, Spain

C. Dasí, M. J. Soler, P. Tomás, I. Fuentes

P-04-010

Cognitive impairment in children and adolescents at high risk for psychosis

J. Tor, Barcelona, Spain

M. Dolz, A. Sintes, O. Puig, C. Espelt, M. Pardo, M. Rodríguez, D. Muñoz, E. De la Serna, I. Baeza

P-04-011

Cognitive deficit in female patients with chronic schizophrenia

M. Mutica, Galati, Romania

M. C. Pirlog, I. Marinescu, D. Marinescu

P-04-013

Factors affecting the structure of cognitive deficit in patients with schizophrenia

M. Dorofeikova, St. Petersburg, Russia

N. Petrova

P-05 POSTER SESSIONS

13:30 – 14:30 Event Area, Ground Floor

Genes and gene-environment interaction

Chair: H. Ehrenreich, Göttingen, Germany

P-05-001

Exome-sequencing in severely affected patients with schizophrenia

*F. Degenhardt, Bonn, Germany
L. Winkler, F. Neukirch, J. Strohmaier, K. U. Ludwig,
F. Schroeder, M. Lang, S. H. Witt, H. Thiele, M. Rietschel,
M. Nöthen*

P-05-002

Using genome-wide association studies to investigate genetic overlap between personality traits and schizophrenia and bipolar disorder

*O. B. Smeland, Oslo, Norway
M.-T. Lo, A. Witoelar, M. T. Tesli, D. A. Hinds, Y. Hu,
J. Y. Tung, S. Djurovic, A. M. Dale, C.-H. Chen, O. A. Andreassen*

P-05-003

Adverse childhood experiences, COMT and BDNF genes: an examination of gene-environment interplay on psychosis proneness

*P. Cristóbal-Narváez, Barcelona, Spain
T. Sheinbaum, A. Rosa, S. Ballespi, M. Mitjavila, M. de Castró-Català, T. R. Kwapil, N. Barrantes-Vidal*

P-05-004

Effects of the T-786C, G894T, and C774T polymorphisms of the endothelial nitric oxide synthase gene on the risk of schizophrenia in Russian subjects

*N. Fattakhov, Tomsk, Russia
L. Smirnova, D. Parshukova, D. Kulikov, L. Litvinova,
A. Semke, S. Ivanova*

P-05-005

Moderating effect of the candidate gene p250GAP in the association between childhood trauma and psychosis liability

*E. Peña, Barcelona, Spain
N. Barrantes-Vidal, M. de Castro-Catala, T. R. Kwapil,
T. Sheinbaum, P. Cristóbal-Narváez, A. Rosa*

P-05-006

The FKBP5 and its moderating role on the psychosis-inducing effects of childhood trauma: new evidences from GxE studies

*M. de Castro-Catala, Barcelona, Spain
N. Barrantes-Vidal, E. Peña, T. Sheinbaum, P. Cristóbal-Narváez, T. R. Kwapil, A. Rosa*

P-05-007

Genetic association of dopamine D2 receptor gene polymorphisms and dopamine supersensitivity psychosis

*M. Takase, Chiba, Japan
N. Kanahara, Y. Oda, H. Watanabe, M. Iyo*

P-05-008

Telomere length in blood cells is related to the chronicity, severity and recurrence rate of schizophrenia

*T. Pawelczyk, Lodz, Poland
B. Szymanska, M. Grancow, M. Kotlicka-Antczak,
A. Pawelczyk*

P-05-009

The possible role of let-7, mir-98 and mir-181 as biomarkers for the low cancer risk in schizophrenic patients

*E. Rizas, Filothei Athens, Greece
N. Sifakas, V. Salpeas, E. Katsantoni, C. Papageorgiou,
V. Zoumpourlis*

P-05-010

Recurrent psychoses and atypical antipsychotics in 22q11.2 microdeletion syndrome

*W. Verhoeven, Venray, The Netherlands
J. Egger*

P-05-012

Replicative association analysis of 45 SNPs in Kazakh patients with schizophrenia

*A. Bocharova, Tomsk, Russia
A. Marusin, K. Saduakasova, G. Svyatova, G. Berezina,
V. Stepanov*

D-01	PRO AND CON DEBATES
14:30 – 16:00	Cambridge, 2nd Floor
Early medication discontinuation in first-episode schizophrenia – beneficial or risky?	
<i>Chair: D. Addington, Calgary, Canada</i>	

D-01-001

Pro-position

L. Wunderink, Groningen, The Netherlands

D-01-002

Sound evidence for high risk of relapse in general with illness progression in some patients
W. Gaebel, Düsseldorf, Germany

S-06	SYMPOSIA
14:30 – 16:00	Oxford, 2nd Floor
The single symptom approach: understanding and treating auditory verbal hallucinations and formal thought disorders	
<i>Chairs: C. Mulert, Hamburg, Germany J. Gallinat, Hamburg, Germany</i>	

S-06-001

Auditory hallucinations and ego-disturbances: imaging of dysfunctional brain networks
J. Gallinat, Hamburg, Germany

S-06-002

The neurobiology of auditory hallucinations: a single symptom approach to schizophrenia
K. Hugdahl, Bergen, Norway

S-06-003

Connectivity disturbances in the language system as target for the treatment of auditory hallucinations with tACS
C. Mulert, Hamburg, Germany

S-06-004

Non-invasive brain stimulation for the treatment of auditory hallucinations: neurobiological and clinical aspects
*W. Strik, Bern, Switzerland
P. Homann, J. Kindler, A. Federspiel, D. Hubl, T. Dierks*

S-07	SYMPOSIA
14:30 – 16:00	Harvard, 1st Floor
Patient perspectives, quality of life and affective symptoms in the early treated course of psychotic disorders	
<i>Chairs: I. Melle, Oslo, Norway J. I. Røssberg, Norway</i>	

S-07-001

Long duration of untreated psychosis – is it partly a design problem?
*K. L. Romm, Oslo, Norway
L.-C. Berentzen, K. Gjermundsen, I. Melle, J. I. Røssberg*

S-07-002

Early clinical recovery in first-episode psychosis: correlates of symptomatic remission at one-year follow-up
*C. Simonsen, Oslo, Norway
A. Faerden, T. Ueland, T. Bjella, K. Romm, A. Berg, K. Sundet, O. Andreassen, I. Melle*

S-07-003

Social anxiety and subjective quality of life in first episode psychosis – a one year follow up study
*E. S. Gardsjord, Oslo, Norway
K. L. Romm, I. Melle, J. I. Røssberg*

S-07-004

Childhood trauma is associated with slower improvement of symptoms: findings from the one-year follow-up of patients with first-episode psychosis
*M. Aas, Oslo, Norway
O. Andreassen, I. Melle*

S-08 SYMPOSIA

14:30 – 16:00 **Stanford, 1st Floor**

Multimodal imaging of the psychosis high-risk state

*Chairs: S. Borgwardt, Basel, Switzerland
P. Allen, London, United Kingdom*

S-08-001

Diffusion tensor imaging changes in emerging psychosis

A. Schmidt, London, United Kingdom

S-08-002

Functional connectivity patterns in the pre-psychotic state

*D. Wotruba, Zurich, Switzerland
R. Buechler, A. Theodoridou, S. Kollias, W. Roessler, K. Heekeren, L. Michels*

S-08-003

Positron emission tomography imaging in subjects at high risk of psychosis

P. Allen, London, United Kingdom

S-08-004

Imaging-supported identification of molecular pathways related to psychosis

A. Papassotiropoulos, Basel, Switzerland

O-02 ORAL PRESENTATIONS

14:30 – 16:00 **Princeton, 1st Floor**

Neuroimaging

Chair: A. Aleman, Groningen, The Netherlands

O-02-001

Mapping depression in schizophrenia: an fMRI study

*V. Kumari, London, United Kingdom
E. Peters, A. Guinn, D. Fannon, T. Russell, A. Sumich, E. Kuipers, S. Williams, D. Ffytche*

O-02-002

Structural and functional brain correlates of at-risk mental state

U. Schall, Callaghan, Australia

O-02-003

Altered theory of mind network activity as an intermediate phenotype of schizophrenia: evidence from healthy relatives and genome-wide supported candidate genes

*S. Mohnke, Berlin, Germany
S. Erk, S. Ripke, N. Romanczuk-Seiferth, C. Wackerhagen, F. Degenhardt, S. Witt, H. Tost, A. Heinz, A. Meyer-Lindenberg, H. Walter*

O-02-004

Aberrant salience and self-relevance processing across the psychosis continuum

*T. Katthagen, Berlin, Germany
A. Pankow, L. Deserno, F. Dammering, H. Walter, N. Kathmann, A. Heinz, F. Schlagenhauf*

O-02-005

Neural correlates of predictive motor timing deficits in schizophrenia

*T. Kasperek, Brno, Czech Republic
J. Losak, J. Huttlova, J. Zubor, P. Lipova, J. Vanicek, M. Bares*

O-02-006

Dynamic internetwork connectivity during working memory: relationships to task performance and dopamine release capacity in healthy controls and unmedicated schizophrenia patients

*C. Cassidy, New York, USA
J. Van Snellenberg, M. Slifstein, Z. Wang, C. Benavides, A. Abi-Dargham, G. Horga*

S-09	SYMPOSIA
16:30 – 18:00	Cambridge, 2nd Floor
New findings about what dopamine does in the prefrontal cortex: relevance to schizophrenia	
<i>Chairs: B. Moghaddam, Pittsburgh, USA</i>	
<i>A. Abi-Dargham, New York, USA</i>	

S-09-001

Could the prefrontal dopaminergic system contribute to the anomalies of parvalbumin interneurons and high-frequency oscillations in schizophrenia patients?

P. Steullet, Lausanne, Switzerland

S-09-002

Prefrontal Cortical Cannabinoid Regulation of the Mesolimbic Dopamine System: Implications for Emotional Dysregulation in Schizophrenia

S. Laviolette, London, Ontario, Canada

S-09-003

A novel role for dopamine regulation of cortical information processing

B. Moghaddam, Pittsburgh, USA

S-09-004

Dopamine neurotransmission in schizophrenia: new findings from combined PET and fMRI studies

A. Abi-Dargham, New York, USA

S-10	SYMPOSIA
16:30 – 18:00	Oxford, 2nd Floor
Autoimmune encephalitis and mild encephalitis – from epidemiology to clinic	
<i>Chairs: K. Bechter, Göttingen, Germany</i>	
<i>S. Najjar, Hempstead, USA</i>	

S-10-001

Epidemiological relationships between infections, autoimmune diseases and severe mental illness

M. Benros, Copenhagen, Denmark

S-10-002

Autoimmune encephalitis presenting with primary psychiatric syndromes

S. Najjar, Hempstead, USA

S-10-003

Neuropsychiatric syndrome relevance of circulating autoantibodies against brain epitopes depends on blood-brain-barrier integrity

H. Ehrenreich, Göttingen, Germany

E. Castillo-Gomez

S-10-004

Frequent minor CSF pathologies in schizophrenia support the mild encephalitis hypothesis

K. Bechter, Göttingen, Germany

S-11	SYMPOSIA
16:30 – 18:00	Harvard, 1st Floor
Social cognition in schizophrenia and beyond	
<i>Chairs: G. Lahera, Madrid, Spain</i>	
<i>W. Wölwer, Düsseldorf, Germany</i>	

S-11-001

Social cognitive biases in psychosis and borderline personality disorders

M. González-Torres, Bilbao, Spain
A. Catalán, M. Gonzalez de Artaza

S-11-002

Social cognitive impairments in schizophrenia and bipolar disorder

G. Lahera, Madrid, Spain

S-11-003

Metacognition in psychosis: concepts and results

G. Salvatore, Rome, Italy
L. Buonocore, D. Catania, G. Dimaggio, A. M. Ferrigno,
P. Lysaker, P. Ottavi, N. Manfredi, A. Pallotta, R. Popolo,
M. G. Proto, A. Sateriale, M. Serio

S-11-004

Social cognitive treatment: impact on social cognition and functional outcome

W. Wölwer, Düsseldorf, Germany

S-12	SYMPOSIA
16:30 – 18:00	Stanford, 1st Floor
Predictive coding and sensory disturbances in schizophrenia: from mice to men	
<i>Chairs: P. Uhlhaas, Glasgow, United Kingdom</i>	
<i>P. Sterzer, Berlin, Germany</i>	

S-12-001

Translational Neuromodeling

K. E. Stephan, Zurich, Switzerland

S-12-002

A hierarchical predictive-coding account for the formation and persistence of delusions

P. Sterzer, Berlin, Germany
K. Schmack

S-12-003

Sensory predictions in schizophrenia: perspectives from MEG

P. Uhlhaas, Glasgow, United Kingdom

S-12-004

Sensory prediction in animal models of schizophrenia

T. Sigurdsson, Frankfurt, Germany

O-01 ORAL PRESENTATIONS

16:30 – 18:00 Princeton, 1st Floor

Early detection and intervention

Chair: S. Singh, Coventry, United Kingdom

O-01-001

The European Psychiatric Association's (EPA) guidance on the early detection of clinical high risk states of psychoses

F. Schultze-Lutter, Bern, Switzerland

a. b. of the EPA guidance group on early detection

O-01-002

Risk of psychotic disorder in offspring of parents with schizophrenia: a meta-analysis

A. Macbeth, Edinburgh, United Kingdom

A. Gumley, S. Harder, S. O'Flaherty

O-01-003

Prevalence of psychosis-risk criteria and symptoms in an inpatient and general population sample of children and adolescents

C. Michel, Bern, Switzerland

B. G. Schimmelmann, F. Schultze-Lutter

O-01-004

The European Psychiatric Association's (EPA) guidance on the early intervention of clinical high risk states of psychoses

S. Ruhrmann, Cologne, Germany

S. Schmidt, F. Schultze-Lutter, B. G. Schimmelmann, J. Klosterkötter

O-01-005

First episode psychosis fidelity scale FEPS-FS

D. Addington, Calgary, Canada

J. Wang, R. Norman, E. McKenzie, R. Melton, T. Sale, G. Bond

O-01-006

First-episode psychosis in Chennai, India and Montreal, Canada: a mixed methods approach to the study of family factors across contexts

S. Iyer, Montreal, Canada

H. Loohuis, M. Pope, E. Schorr, G. Mohan, P. Ramachandran, T. Rangaswamy, A. Malla

S-13	SYMPOSIA
08:30 – 10:00	Cambridge, 2nd Floor
Neuroimaging approaches to understanding negative symptoms	
<i>Chairs: A. Aleman, Groningen, The Netherlands</i>	
<i>S. Kaiser, Zurich, Switzerland</i>	

S-13-001

Brain structure abnormalities in first-episode psychosis patients with persistent apathy

L. Mørch-Johnsen, Oslo, Norway

R. Nesvåg, A. Faerden, U. K. Haukvik, K. N. Jørgensen, E. H. Lange, O. A. Andreassen, I. Melle, I. Agartz

S-13-002

Differential neural correlates of apathy and diminished expression in patients with schizophrenia?

S. Kaiser, Zurich, Switzerland

S-13-003

Reward system dysfunction and connectivity subgroups in schizophrenia – relation to negative symptoms

F. Schlagenhauf, Berlin, Germany

L. Deserno, A. Heinz

S-13-004

Involvement of brain networks subserving executive functioning versus social-emotional appraisal in negative symptoms

A. Aleman, Groningen, The Netherlands

S-14	SYMPOSIA
08:30 – 10:00	Oxford, 2nd Floor
Modulating neural plasticity for the treatment of schizophrenia	
<i>Chairs: A. Hasan, Munich, Germany</i>	
<i>J. Brunelin, Bron, France</i>	

S-14-001

Individualized non-invasive brain stimulation in schizophrenia

T. Dierks, Switzerland

P. Homan, J. Kindler, D. Hubl

S-14-002

Non-invasive brain stimulation to improve cognition in schizophrenia

C. Plewnia, Tübingen, Germany

S-14-003

Effects of tDCS on auditory hallucinations and self recognition

J. Brunelin, Bron, France

M. Mondino, E. Poulet

S-14-004

Efficacy and biological impact of rTMS in pre-dominant negative symptoms

A. Hasan, Munich, Germany

T. Wobrock

S-15	SYMPOSIA
08:30 – 10:00	Harvard, 1st Floor
Depressive episodes in the course of schizophrenia-spectrum disorders: clinical challenges, therapeutic strategies	
<i>Chairs: S. Englisch, Mannheim, Germany</i>	
<i>C. U. Correll, Glen Oaks, USA</i>	

S-15-001

Evaluating depressive symptoms in schizophrenia – a psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale

I. Spellmann, Germany

R. Schennach, R. Musil, M. Obermeier, F. Seemüller, M. Riedel, H.-J. Möller

S-15-002

Efficacy of antidepressants for positive, negative and cognitive symptoms in schizophrenia: critical analysis derived from randomized clinical trials

C. U. Correll, Glen Oaks, USA

S-15-003

Agomelatine for the treatment of depressive episodes in the course of schizophrenia-spectrum disorders: data from the AGOPSYCH study

S. Englisch, Mannheim, Germany

S-15-004

Cognitive behavioural therapy for the treatment of depressive episodes in schizophrenia: modes of implementation, management of challenges

T. Lincoln, Hamburg, Germany

S-16	SYMPOSIA
08:30 – 10:00	Stanford, 1st Floor
Clozapine: the art of prescribing	
<i>Chairs: D. Cohen, Heerhugowaard, The Netherlands</i>	
<i>D. Rujescu, Halle, Germany</i>	

S-16-001

Agranulocytosis and mortality: myths and facts

P. Schulte, Alkmaar, The Netherlands

S-16-002

Grinded in porridge and other strategies to enhance clozapine administration in non-compliant patients

D. van Dijk, Oegstgeest, The Netherlands

D. Cohen, J. Bogers

S-16-003

Clozapine resistance: what is a rational pharmacotherapeutic next step?

J. Bogers, Oegstgeest, The Netherlands

D. Cohen

S-16-004

Separating chaff from wheat: evidence-based monitoring in clozapine therapy

D. Cohen, Heerhugowaard, The Netherlands

S-17	SYMPOSIA
08:30 – 10:00	Princeton, 1st Floor
Bridging animal-human NMDAR models of schizophrenia through EEG biomarkers in behaving rodents and humans	
<i>Chairs: C. Haenschel, London, United Kingdom P. Michie, Newcastle, Australia</i>	

S-17-001

Neural oscillations, mismatch negativity and NMDA-receptors: perspectives from magnetoencephalography

P. Uhlhaas, Glasgow, United Kingdom

S-17-002

Acute effects of MK-801 on deviance detection (including MMN-like) potentials in the awake rat

P. Michie, Newcastle, Australia

L. Harms

S-17-003

Effects of acute ketamine infusion on visual working memory

C. Haenschel, London, United Kingdom

I. Koychev, W. El-Deredy, B. Deakin

S-17-004

Bridging animal-human NMDAR models of schizophrenia through EEG biomarkers in behaving rodents

E. Hong, Catonsville, USA

E. Sullivan, P. O'Donnell

S-18	SYMPOSIA
10:30 – 12:00	Cambridge, 2nd Floor
Impact of negative symptoms on schizophrenia functional outcome	
<i>Chairs: S. Galderisi, Naples, Italy J. K. Rybakowski, Poznan, Poland</i>	

S-18-001

Modeling relationships between negative symptoms and functioning in real-life

S. Galderisi, Naples, Italy

A. Rossi, P. Rocca, A. Bertolino, A. Mucci, P. Bucci,

M. Maj

S-18-002

Persistent negative symptoms and outcome in first-episode patients with schizophrenia

A. Üçok, Istanbul, Turkey

C. Ergül

S-18-003

The impact of negative symptoms on long-term course of schizophrenia

J. K. Rybakowski, Poznan, Poland

S-18-004

Negative symptoms, early intervention and outcome in first episode psychosis

I. Melle, Oslo, Norway

S-19	SYMPOSIA
10:30 – 12:00	Oxford, 2nd Floor
Verbal and nonverbal communication deficits in schizophrenia	
<i>Chairs: S. Walther, Bern, Switzerland</i>	
<i>T. Kircher, Marburg, Germany</i>	

S-19-001

Gesture-speech mismatch and lexical retrieval gestures in the psychosis prodrome

D. Dean, Boulder, USA

V. Mittal, J. Bernard, Z. Millman

S-19-002

The neural correlates of natural social-communicative perception processes in patients with schizophrenia: Comprehension, recognition and interpretation of verbal and non-verbal information

B. Straube, Marburg, Germany

M. Straube, T. Kircher, A. Nagels

S-19-003

The link between impaired performance of hand gestures and poor nonverbal social perception in schizophrenia and first degree relatives

S. Walther, Bern, Switzerland

K. Stegmayer, J. Sulzbacher, S. Bohlhalter, W. Strik

S-19-004

Formal thought disorder: dissecting its internal structure and neural correlates

T. Kircher, Marburg, Germany

S-20	SYMPOSIA
10:30 – 12:00	Harvard, 1st Floor
Psychological treatments for posttraumatic stress disorder in psychosis: feasibility, safety and efficacy	
<i>Chairs: M. van der Gaag, Oegstgeest, The Netherlands</i>	
<i>A. Hardy, London, United Kingdom</i>	

S-20-001

Cognitive behavioural therapy for the treatment of posttraumatic stress disorder in schizophrenia

A. Hardy, London, United Kingdom

C. Steel, B. Smith, T. Wykes, S. Rose, S. Enright, M. Hardcastle, J. Gottlieb, D. Rose, K. Mueser

S-20-002

Trauma, psychosis and the prevalence of PTSD in people with psychotic disorders

P. de Bont, Bosmeer, The Netherlands

S-20-003

Prolonged exposure versus eye movement desensitization and reprocessing versus waiting list for posttraumatic stress disorder in patients with a psychotic disorder

D. van den Berg, The Hague, The Netherlands

S-20-004

Daily life of patients with psychosis and post-traumatic stress: an experience sampling study

B. van der Vleugel, Alkmaar, The Netherlands

D-02 PRO AND CON DEBATES

10:30 – 12:00 Stanford, 1st Floor

Should "schizophrenia" be renamed?

Chair W. Gaebel, Düsseldorf, Germany

D-02-001

Schizophrenia: time has come to consign this stigmatising label to history

A. Lasalvia, Verona, Italy

D-02-002

Language disguises thought

S. Priebe, London, United Kingdom

S-21 SYMPOSIA

10:30 – 12:00 Princeton, 1st Floor

Neuroinflammation and infection in schizophrenia

Chairs: A. Sutterland, Amsterdam, The Netherlands

I. Sommer, Utrecht, The Netherlands

S-21-001

GWAS in Psychiatry: using polygenic risk scores to dissect an inflammatory subtype of schizophrenia; an experimental approach

S. Ripke, Berlin, Germany

S-21-002

Immune activation in schizophrenia: evidence from the post-mortem field

I. Sommer, Utrecht, The Netherlands

C. van Kesteren

S-21-003

The association of toxoplasma gondii with psychiatric disorders. A systematic review and meta-analysis

A. Sutterland, Amsterdam, The Netherlands

G. Fond, A. Kuin, M. Koeter, R. Lutter, T. van Gool, R. Yolken, A. Szoke, M. Leboyer, L. de Haan

S-21-004

Treatment with Anti-Toxoplasmic Activity (TATA) for toxoplasma positive patients with bipolar disorders or schizophrenia

G. Fond, Creteil, France

N. Hamdani, M. Leboyer

PL-02 PLENARY LECTURES

12:15 – 13:00 **B** Cambridge, 2nd Floor

Perspectives of drug development for the treatment of schizophrenia

Chair: H.-J. Möller, Munich, Germany

PL-02-001

Perspectives of drug development for the treatment of schizophrenia

J. Rabinowitz, Ramat Gan, Israel

B Broadcasting of Plenary Lecture in room Oxford

P-06	POSTER SESSIONS
13:30 – 14:30	Event Area, Ground Floor
Neurobiology and animal models	
Chair: K. Bechter, Güzburg, Germany	

P-06-001

So called D-neuron (= trace amine neuron): a new clue for schizophrenia research

K. Ikemoto, Iwaki, Japan

P-06-002

First episode of schizophrenia is followed by conformational and functional disturbances of serum albumin

M. Uzbekov, Moscow, Russia

T. Syrejschikova, T. Babushkina, N. Smolina, V. Kalinina, G. Dobretsov, T. Klimova, A. Peregudov, S. Shikhov

P-06-003

Abnormal C-reactive protein (CRP) levels in schizophrenia and schizoaffective disorders. Results from the FACE-SZ data-set

G. Fond, Creteil, France

O. Godin, P.-M. Llorca, M. Leboyer

P-06-004

Cycloid psychoses versus schizophrenia: different biochemical profiles?

N. van der Kerkhof, Venray, The Netherlands

D. Fekkes, F. Van der Heijden, W. Verhoeven

P-06-005

Spironolactone inhibits Nrg1-ErbB4 signalling to improve schizophrenia-relevant endophenotypes in Nrg1 transgenic mice

M. Wehr, Munich, Germany

W. Hinrichs, M. Brzozka, T. Unterbarnscheidt, S. Wichert, M. Schwab, M. Rossner

P-06-006

Distribution of neuropeptide Y in the frontal cortex of, a model mouse of schizophrenia, DISC1 knockout mouse

S. Morosawa, Nagoya Aichi, Japan

S. Iritani, T. Marui, K. Umeda, H. Sekiguchi, Y. Torii, H. Fujishiro, K. Kuroda, K. Kaibuchi, N. Ozaki

P-06-007

The role of alpha-2 adrenergic receptors on pre-pulse inhibition of acoustic startle reflex in rats

T. Uzbay, Istanbul, Turkey

A. Ozcetin, B. Cevreli

P-06-008

New approach for the synthesis of analgetic 2-azabicyclo[3.3.1]nonane scaffolds

V. Palchikov, Dnipropetrovsk, Ukraine

P-06-009

The novel antipsychotic PGW5, a sarcosinyl-linked Olanzapine, exhibits high efficacy in rodent schizophrenia models, without metabolic side-effects

I. Gil-Ad, Petah-Tikva, Israel

M. Portnoy, M. Taler, A. Weller, A. Weizman

P-06-010

Identification of a novel molecular pathway for cannabidiol's antipsychotic properties in the mesolimbic pathway: role of mTOR/p70S6 kinase signalling

J. Renard, London, Canada

M. Loureiro, L. Rosen, W. Rushlow, S. Laviolette

P-06-011

The antipsychotic-like effects of LSP4-2022 in positive, negative and cognitive symptoms in schizophrenia

M. Wozniak, Cracow, Poland

J. Wieronska, F. Acher, A. Pilc

P-06-012

The ergoline 2-bromoterguride produces anti-psychotic-like effects in rats

J. Brosda, Berlin, Germany

R. T. Franke, A. E. Tarland, H. H. Pertz, H. Fink

P-07 POSTER SESSIONS

13:30 – 14:30

Foyer, 2nd Floor

Outcome

Chair: A. G. Awad, Toronto, Canada

P-07-001

Treatment outcomes of patients with severe schizophrenia undergoing specific severe mental illness programme. A 6-year follow-up

J. J. Fernandez Miranda, Gijón, Spain

S. Diaz-Fernandez

P-07-002

Objective predictors of outcome in forensic mental health services: a systematic review

O. Sedgwick, London, United Kingdom

S. Young, M. Das, V. Kumari

P-07-003

Comparison of experienced burden and distress among families of patients with schizophrenia and bipolar disorder

S. M. Samimi Ardestani, Tehran, Iran

M. Radmanesh

P-07-004

Determinants of meaning in life in patients with severe mental disorders

P. Huguelet, Geneva, Switzerland

P-07-005

The impact of apathy on vocational outcome and on vocational rehabilitation

H. Bull, Oslo, Norway

T. Ueland, J. Lystad, S. Evensen, E. Falkum

P-07-006

The effect of thought disorders on remission of symptoms in schizophrenia

K. Alptekin, Izmir, Turkey

B. Yalinçetin, H. Ulas, T. Binbay, B. B. Akdede

P-07-007

The impact of negative symptoms on psychopathological status, social functioning and quality of life during long-term follow-up of the first episode of schizophrenia

J. K. Rybakowski, Poznań, Poland

K. Gorna, K. Jaracz, J. Jaracz, J. Kiejda, B. Grabowska-Fudala, M. Wilkiewicz, A. Suwalska

P-07-008

The functioning puzzle in schizophrenia: chronicity, symptoms, cognition. What is the key factor?

A. Brañas, Alcalá de Henares, Madrid, Spain

M. Vicens, A. Ruiz, A. Orozco, G. Lahera

P-07-009

Surviving schizophrenia in the family: four case studies

P. P. Espinosa, Daejeon, Republic of Korea

P-07-010

Attitudes towards patients with psychosis and depression in the general population: effects of labeling

C. Michel, Bern, Switzerland

B. G. Schimmelmann, F. Schultze-Lutter, N. Schnyder

P-07-011

Improving media depiction about schizophrenia and mental illness: evaluation results of workshops for screenwriters and journalists

H. Becker, Duesseldorf, Germany

H. Zäske, A. Ramge, W. Gaebel

P-07-012

Mental health literacy: is psychosis as well recognized as depression?

C. Michel, Bern, Switzerland

B. G. Schimmelmann, F. Schultze-Lutter, N. Schnyder

P-08	POSTER SESSIONS
13:30 – 14:30	Sorbonne 2, 2nd Floor
Psychosocial factors and interventions	
<i>Chair: M. van der Gaag, Oegstgeest, The Netherlands</i>	

P-08-001

Emotional changes in a group of recent onset psychotic patients receiving a metacognitive intervention (MCT)

E. Lorente-Rovira, Valencia, Spain

A. Luengo, A. Guasp, B. Llacer, J. M. Carot, J. Sanjuan, S. metacognitive group

P-08-002

Complex approaches to social cognitive interventions in patients with schizophrenia

O. Papsuev, Moscow, Russia

N. Semenova, L. Movina, M. Minyaycheva, O. Limankin, A. Naryshkin, M. Sheifer, I. Gurovich

P-08-003

Enhancing motivation in persons with schizophrenia: general guidelines, starting points and issues of evaluation

N. Semenova, Moscow, Russia

P-08-004

Functional resource of the family as a biopsychosocial predictor of adaptive behaviour of schizophrenic patients

E. Gutkevich, Tomsk, Russia

A. Semke, Y. Maltseva

P-08-005

Self-disgust and fear of compassion: new approaches to paranoid ideation

M. J. Martins, Coimbra, Portugal

P. Castilho, D. Carvalho, C. Pascoal

P-08-006

Feasibility and effects of a brief compassion-focused imagery intervention in psychotic patients with paranoid ideation: a randomized experimental study

L. Ascone Michelis, Hamburg, Germany

J. Sundag, B. Schlier, T. Lincoln

P-08-007

Correlations between cardiorespiratory fitness, physical activity and symptoms of disease in patients with schizophrenia – preliminary results

S. Ginsel, Oldenburg, Germany

M. Brandes, C. Figge

P-08-008

Mechanism of improvement in functional competence in schizophrenia after cognitive rehabilitation

N. Ojeda, Bilbao, Spain

J. Peña, N. Ibarretxe-Bilbao, P. Sanchez, E. Elizagarate,

J. Ezcurra, M. Gutierrez

P-08-009

Current but not past social defeat is associated with psychotic symptoms

E. Jaya, Hamburg, Germany

T. Lincoln

P-08-010

Cognitive remediation in schizophrenia

J. Cañete Crespillo, Mataro, Spain

C. Palma, C. Torres, C. Corte

P-08-011

Implementation of a new psychosocial training "Social Cognition Individualized Activities Lab": a pilot study

D. Palumbo, Naples, Italy

G. Piegari, M. Chieffi, A. Mazza, R. Giugliano, F. De

Riso, V. D'Alise, A. Mucci, S. Galderisi

P-09 POSTER SESSIONS

13:30 – 14:30 Event Area, Ground Floor

Neuropsychology II

Chair: D. Freeman, Oxford, United Kingdom

P-09-001

Visual attention deficits in 7-year-old children of parents with schizophrenia or bipolar disorder – part of the Danish high risk and resilience study via 7

N. Hemager, Hellerup, Denmark

P-09-002

The predicted value of clinical symptoms on the cognitive performance in adolescents at risk for schizophrenia or affective psychosis results from the Harvard adolescent family high risk study

J. Peña, Bilbao, Spain

R. Del Pino Saez, R. Mesholam-Gately, W. S. Stone, N. Ojeda del Pozo, M. T. Tsuang, S. Faraone, L. J. Seidman

P-09-003

Interactive decision-making in patients with schizophrenia: a systematic review

A. Kaltenboeck, Vienna, Austria

B. Hinterbuchinger, F. Friedrich, N. Mossaheb

P-09-004

Effects of age and educational level on cognitive functioning in schizophrenia

K. Pantelis, Larisa, Greece

K. Bonotis, V. Chatzi, E. Kita, S. Karaoulanis, D. Kremeti

P-09-005

Course of cognitive impairment in psychosis according to time of evolution after diagnosis

L. Rodriguez Blanco, Madrid, Spain

L. Mata Iturralde, L. Dorado Jimenez, A. Vian, L. Muñoz Lorenzo

P-09-006

Neurocognition and occupational functioning in schizophrenia spectrum disorders: the MATRICS Consensus Cognitive Battery (MCCB) and workplace assessments

J. Lystad, Oslo, Norway

E. Falkum, V. Øksendal Haaland, H. Bull, S. Evensen, T. Ueland

P-09-007

Emotional processing in acute psychosis

A. González-Barroso, Madrid, Spain

A. Ruiz, B. Martínez, M. García, G. Lahera

P-09-008

Emotional intelligence in subjects with a first psychotic episode and its correlation with pre-morbid intelligence quotient

D. Treen, Barcelona, Spain

R. Cortizo, D. Berge, A. Mane

P-09-009

Decreased right-handedness and cerebral asymmetry in youth at ultrahigh risk for psychosis

D. Dean, Boulder, USA

J. Orr, V. Mittal

P-09-010

Dimensions of schizotypy in relation to different types of predictive processing and source-monitoring

C. Humpston, Cardiff, United Kingdom

L. Evans, C. Teufel, J. Ingram, D. Wolpert, D. Linden

P-09-011

Measuring aberrant salience attribution in patients with schizophrenia

F. Dammering, Magdeburg, Germany

T. Katthagen, A. Heinz, N. Kathmann, F. Schlagenhauf

P-09-012

Assessment of the suicide and violence potential indices using the Personality Assessment Inventory (PAI) in a forensic schizophrenic patient sample

I. S. Chee, Daejeon, Republic of Korea

S.-K. Wang, J. H. Kwon, J. L. Kim

P-09-013

Aberrant speech illusions in first episode psychosis

V. Angosto, Bilbao, Spain

A. Catalan Alcantara, C. Valverde, F. Aguirregomescorta, S. Bustamante, A. Madrazo, A. Fernandez, M. A. Gonzalez-Torres

P-10	POSTER SESSIONS
13:30 – 14:30	Event Area, Ground Floor
Neuroimaging I	
Chair: T. Kircher, Marburg, Germany	

P-10-001

Aberrant salience is related to dysfunctional self-referential processing in psychosis

T. Katthagen, Berlin, Germany

A. Pankow, S. Diner, L. Deserno, R. Boehme, T. Gleich, M. Gaebler, H. Walter, A. Heinz, F. Schlagenhauf

P-10-002

Impaired insight and affective theory of mind in patients with schizophrenia: a fMRI study

A. de Vos, Assen, The Netherlands

M. Pijnenborg, D. Larabi, L. Steenhuis, C. Hooker, L. van der Meer, A. Aleman

P-10-003

Common and distinct neural effects of risperidone and olanzapine during procedural learning in schizophrenia

V. Kumari, London, United Kingdom

U. Ettinger, S. Lee, C. Deuschl, A. Anilkumar, A. Schmechtig, P. Corr, D. Ffytche, S. Williams

P-10-004

Is it me? Self-monitoring neural network and insight in schizophrenia

A. Sapara, London, United Kingdom

D. Ffytche, M. Cooke, S. C. R. Williams, V. Kumari

P-10-005

Neural correlates of intentional behaviour in a healthy population with high and low apathy

C. Kos, Groningen, The Netherlands

N. Klaasen, E. Opmeer, H. Knegtering, M.-J. van Tol, A. Aleman

P-10-006

Is subclinical apathy related to neural alterations during set-shifting?

N. Klaasen, Groningen, The Netherlands

C. Kos, A. Aleman, E. Opmeer

P-10-007

Schizophrenia patients with high negative symptoms show altered fronto-parietal activation during working memory

J. Kaminski, Berlin, Germany

L. Shayegan, Y. Fukuda, T. Katthagen, L. Deserno, A. Heinz, F. Schlagenhauf

P-10-008

Improved correspondence of cortical working memory networks in patients with schizophrenia after macro-anatomical alignment of functional magnetic resonance imaging data

R. Bittner, Frankfurt, Germany

D. Linden, A. Kolomiets, M. Frost, R. Goebel, C. Haenschel

P-10-009

Inefficient DLPFC recruitment in delusion-prone subjects during a working memory task

Y. Fukuda, Berlin, Germany

T. Katthagen, L. Deserno, F. Schlagenhauf

P-10-010

Interactions between visual attention and spatial working memory encoding in schizophrenia: a fMRI study

J. Mayer, Frankfurt Am Main, Germany

F. Fußer, C. Rickmeyer, R. Bittner, L. Rösler, C. Haenschel

P-10-011

Fronto-limbic novelty processing in acute psychosis: inefficient hippocampal encoding and potential implications for delusions

B. Schott, Berlin, Germany

M. Voss, B. Wagner, T. Wüstenberg, E. Düzel, J. Behr

S-22	SYMPOSIA
14:30 – 16:00	Cambridge, 2nd Floor
Symptom dimensions and their clinical implication in schizophrenia	
<i>Chairs: A. Heinz, Berlin, Germany</i>	
<i>W. Gaebel, Düsseldorf, Germany</i>	

S-22-001

Connectivity in the language system during formal thought disorders

W. Strik, Bern, Switzerland
K. Laimboeck, A. Federspiel, S. Walther, K. Stegmayer, H. Horn

S-22-002

Dimensions of motor dysfunctions in schizophrenia and schizophrenia spectrum disorders

Y. Zaytseva, Klecany, Czech Republic
N. Korsakova, I. Gurovich, A. Heinz, M. Rapp

S-22-003

Symptom dimensions and real-life functioning in people with schizophrenia

S. Galderisi, Naples, Italy
A. Rossi, P. Rocca, A. Bertolino, A. Mucci, P. Bucci, M. Maj

S-22-004

Neurobiological subtypes of altered executive functions and decision making in schizophrenia

F. Schlagenhauf, Berlin, Germany
Q. Huys, L. Deserno, A. Heinz

S-23	SYMPOSIA
14:30 – 16:00	Oxford, 2nd Floor
Lifespan development of schizophrenia and how the treatments improve it	
<i>Chairs: M. Isohanni, Oulu, Finland</i>	
<i>H.-J. Möller, Munich, Germany</i>	

S-23-001

Lifespan development of brain in schizophrenia and population

N. Koutsouleris, Munich, Germany

S-23-002

Longitudinal development of cognition in schizophrenia

A. Husa, Oulu, Finland
I. Rannikko, J. Moilanen, P. Juola, G. Murray, J. Barnett, R. Marttila, M. Haapea, H. Koponen, M. Isohanni, J. Miettunen, E. Jääskeläinen

S-23-003

Somatic comorbidity and its outcomes in schizophrenia during lifespan

J. Seppälä, Oulu, Finland
M. Isohanni, E. Jääskeläinen, J. Miettunen, T. Nordström, J. Auvinen, N. Rautio

S-23-004

Antipsychotic medication and outcomes in schizophrenia from a lifespan perspective

H. Koponen, Helsinki, Finland

S-24	SYMPOSIA
14:30 – 16:00	Harvard, 1st Floor
Improving outcomes: factors influencing help seeking behavior, duration of untreated psychosis and treatment outcome in immigrants and ethnic minorities with first episode psychosis	
<i>Chairs: I. Melle, Oslo, Norway A. Bechdolf, Berlin, Germany</i>	

S-24-001

Help seeking behavior of migrants with early psychosis – first data from the FRITZ project in Berlin

*A. Bechdolf, Berlin, Germany
K. Leopold, S. Laier*

S-24-002

Migrant background and ethnic minority status as predictors for duration of untreated psychosis

*M. Nerhus, Oslo, Norway
A. Berg, I. Melle*

S-24-003

Clinical and socio-cultural measures of insight in immigrants in their first episode of psychosis

*A. O. Berg, Oslo, Norway
M. Nerhus, E. Barrett, I. Melle*

S-24-004

Psychopathology, cognition and functional recovery: differences between Dutch and immigrant first-episode psychosis patients

*L. Stouten, The Hague, The Netherlands
W. Veling, W. Laan, M. van der Gaag*

S-25	SYMPOSIA
14:30 – 16:00	Stanford, 1st Floor
Detecting psychosis proneness: schizotypy and clinical high risk	
<i>Chairs: F. Schultze-Lutter, Bern, Switzerland M. Debbané, Geneva, Switzerland</i>	

S-25-001

Detecting psychosis proneness: schizotypy and clinical high risk

M. Debbané, Geneva, Switzerland

S-25-002

Ecological phenotypes in schizotypy and clinical high risk

*T. Sheinbaum, Barcelona, Spain
N. Barrantes-Vidal*

S-25-003

Predictive value of the Wisconsin Schizotypy scales in a clinical high risk sample

*F. Schultze-Lutter, Bern, Switzerland
S. Ruhrmann, B. G. Schimmelmann, J. Klosterkötter,
C. Michel, R. Flückiger*

S-25-004

Is cognitive profiling worth the effort?

*C. Mohr, Lausanne, Switzerland
D. Herzig*

S-26	SYMPOSIA
14:30 – 16:00	Princeton, 1st Floor
Disturbed connectivity in schizophrenia: from dysfunctional white matter tracts to molecular findings	
<i>Chairs: A. Schmitt, Munich, Germany J. Steiner, Magdeburg, Germany</i>	

S-26-001

Changes of connectivity in multi-episode schizophrenia: a multimodal imaging study
B. Malchow, Munich, Germany

S-26-002

S100B downregulation in the nuclear proteome of schizophrenia corpus callosum
*J. Steiner, Magdeburg, Germany
A. Schmitt, B. Bogerts, D. Martins-de-Souza*

S-26-003

Oligodendrocyte pathology and association with cognitive deficits in schizophrenia
P. Falkai, Munich, Germany

S-26-004

Oligodendrocyte dysfunction in schizophrenia from a proteomic point of view
D. Martins-de-Souza, Campinas, Brazil

S-27	SYMPOSIA
16:30 – 18:00	Cambridge, 2nd Floor
The role of psychotherapy in the treatment of schizophrenia	
<i>Chairs: A. Bechdolf, Berlin, Germany M. van der Gaag, Oegstgeest, The Netherlands</i>	

S-27-001

Psychotherapy in people with positive symptoms
S. Klingberg, Tübingen, Germany

S-27-002

Psychotherapy in people with negative symptoms
*M. van der Gaag, Oegstgeest, The Netherlands
E. Velthorst, F. Smit, C. Meyer, M. Koeter, A.-K. Fett,
A. B. Staring, L. de Haan*

S-27-003

Cognitive remediation in schizophrenia
W. Wölwer, Düsseldorf, Germany

S-27-004

Psychotherapy in people at clinical high risk of psychosis
A. Bechdolf, Berlin, Germany

S-28	SYMPOSIA
16:30 – 18:00	Oxford, 2nd Floor
Assessment of negative symptoms: challenges and recent developments	
<i>Chairs: T. Lincoln, Hamburg, Germany</i>	
<i>M. Lambert, Hamburg, Germany</i>	

S-28-001

Implications of overlap between negative symptom measurement and other aspects of psychosis

J. P. Lyne, Dublin, Ireland

M. Clarke

S-28-002

Validation of the German version of The Clinical Assessment Interview for Negative Symptoms (CAINS)

M. Engel, Hamburg, Germany

T. Lincoln

S-28-003

Self-assessments of negative symptoms in schizophrenia

V. Marzloff, Caen, France

S. Dollfus, C. Mach, R. Morello

S-28-004

How does self-assessment of apathy differ from the clinician's assessment of apathy?

A. Faerden, Oslo, Norway

S-29	SYMPOSIA
16:30 – 18:00	Harvard, 1st Floor
Paranoia as a symptom dimension in schizophrenia	
<i>Chairs: W. Strik, Bern, Switzerland</i>	
<i>D. Freeman, Oxford, United Kingdom</i>	

S-29-001

Paranoia, psychotic anxiety and the emotional brain

W. Strik, Bern, Switzerland

K. Stegmayer, S. Walther, A. Federspiel

S-29-002

Paranoia: advances in understanding and treatment

D. Freeman, Oxford, United Kingdom

S-29-003

Contribution of aberrant salience attribution to delusions

F. Schlagenhauf, Berlin, Germany

S-29-004

Structural abnormalities in the ventral striatum and the pathological perception of threat in schizophrenia

K. Stegmayer, Bern, Switzerland

W. Strik, T. Bracht, S. Walther

S-30	SYMPOSIA
16:30 – 18:00	Stanford, 1st Floor
Predicting psychosis – methodological concepts and first findings of the 'Personalised Prognostic Tools for Early Psychosis Management' (PRONIA) project	
<i>Chairs: N. Koutsouleris, Munich, Germany R. K. R. Salokangas, Turku, Finland</i>	

S-30-001

Multivariate clinical prediction of psychosis and its early course

*S. Ruhrmann, Cologne, Germany
N. Kaiser, M. Rosen, T. Haidl, S. Borgwardt, P. Brambilla,
R. K. R. Salokangas, W. Stephen, N. Koutsouleris*

S-30-002

Automatic prediction of psychosis using cognitive measures: the PRONIA approach

*C. Bonivento, Udine, Italy
P. Brambilla, S. Piccin, M. Garzitto, M. Re, A. Ferro,
G. Cabras*

S-30-003

Studying cross-center MRI scanner variations: initial experience from the PRONIA calibration study

*C. Lenz, Basel, Switzerland
N. Koutsouleris, C. Cabral, P. Brambilla, S. Ruhrmann,
S. J. Wood, R. K. R. Salokangas, S. Borgwardt*

S-30-004

Predicting outcomes other than psychosis: past experiences and future approaches

S. Wood, Birmingham, United Kingdom

O-03	ORAL PRESENTATIONS
16:30 – 18:00	Princeton, 1st Floor
Drug treatment	
<i>Chair: J. K. Rybakowski, Poznan, Poland</i>	

O-03-001

The impact of newer anti-psychotics on patient-centered outcomes in schizophrenia – beyond efficacy and into effectiveness

A. G. Awad, Toronto, Canada

O-03-002

Determination of adherence profiles in schizophrenia using the Medication Adherence Rating Scale (MARS): results from the FACE-SZ cohort

*D. Misdrahi, Bordeaux, France
A. Tessier, P. M. Llorca, G. Fond*

O-03-003

The problem of non-compliance during treatment of schizophrenia

*G. Bogojevic, Belgrade, Serbia
D. Zigmund, L. Ziravac*

O-03-004

Memantine augmentation in clozapine refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study

*P. Schulte, Alkmaar, The Netherlands
S. Veerman, J. Smith, L. de Haan*

O-03-005

Delayed initiation of clozapine may be related with poor response in treatment-resistant schizophrenia

A. Üçok, Istanbul, Turkey

O-03-006

Prevalence, incidence and risk factors for anti-psychotic-induced movement disorders

*T. Mentzel, Amersfoort, The Netherlands
R. Lieverse, J. van Os, P. van Harten*

S-31	SYMPOSIA
18:15 – 19:45	Oxford, 2nd Floor
Avolition and asociality: bridging gaps between animal and human research	
<i>Chairs: A. Mucci, Naples, Italy</i>	
<i>S. Walther, Bern, Switzerland</i>	

S-31-001

Pathophysiological mechanisms of avolition in deficit schizophrenia

A. Mucci, Naples, Italy

S. Galderisi

S-31-002

Longitudinal course of two measures of avolition and expressivity: hypokinesia and gesture impairment

S. Walther, Bern, Switzerland

K. Stegmayer

S-31-003

NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans

J. Neill, Manchester, United Kingdom

S-31-004

Animal models of the genetic contribution to avolition and anhedonia: relevance to human research

C. O'Tuathaigh, Cork, Ireland

S-32	SYMPOSIA
18:15 – 19:45	Harvard, 1st Floor
Social cognition in schizophrenia – new task developments and establishing paradigms	
<i>Chairs: K. Kölkebeck, Münster, Germany</i>	
<i>V. Fuglsang Bliksted, Aarhus, Denmark</i>	

S-32-001

Ambiguous emotion identification in schizophrenia: preliminary findings of a novel assessment task with culturally unfamiliar stimuli

K. Kölkebeck, Münster, Germany

A. Vosseler, T. Fasshauer, W. Kohl, S. Minoshita, S. Satoh, R. Lencer

S-32-002

New tools for assessing social cues in schizophrenia

R. Fusaroli, Aarhus, Denmark

A. Simonsen

S-32-003

An fMRI study of theory of mind in first-episode psychosis

C. F. Bartholomeusz, Parkville, Australia

E. Ganella, S. Whittle, A. Abu-Akel, K. Allott, A. Thompson, P. McGorry, E. Killackey, C. Pantelis, S. Wood

S-32-004

Social cognitive subgroups in first-episode schizophrenia based on fMRI and psychological assessment

V. Fuglsang Bliksted, Aarhus, Denmark

S-33 SYMPOSIA

18:15 – 19:45 Stanford, 1st Floor

Schizophrenia as neurodevelopmental disorder and effects of antipsychotic treatment: new insights from animal models

*Chairs: A. Schmitt, Munich, Germany
M. von Wilmsdorff, Düsseldorf, Germany*

S-33-001

The SRGAP3-/- mouse: an animal model for disturbed brain development in schizophrenia
R. Waltereit, Dresden, Germany

S-33-002

Glutamatergic dysfunction in mice with inducible ablation of GluA1 AMPA receptors during adolescence
D. Inta, Mannheim, Germany

S-33-003

The role of perinatal hypoxia in transgenic TCF4 mice as animal model of etiological factors in schizophrenia
*A. Schmitt, Munich, Germany
M. Rossner, D. Inta, C. Dormann, P. Gass, M. Brzozka, P. Falkai*

S-33-004

Effects of antipsychotic treatment on synaptic plasticity in animal models of perinatal hypoxia during early adulthood
*M. von Wilmsdorff, Düsseldorf, Germany
F. Manthey, P. Gebicke-Härter, W. Gaebel, A. Schmitt*

O-04 ORAL PRESENTATIONS

18:15 – 19:45 Princeton, 1st Floor

Comorbidity

Chair: G. Heinze Martin, Mexico

O-04-001

Association between substance abuse and long-term outcome of schizophrenia – a meta-analysis
*J. Miettunen, Oulu, Finland
T.-M. Paaso, K. Kasurinen, N. Hirvonen, A. Mustonen, E. Oinas, J. Käkälä, E. Jääskeläinen*

O-04-002

Prevalence of vitamin D deficiencies in Dutch outpatients with schizophrenia, schizoaffective or bipolar disorder
*P. Schulte, Alkmaar, The Netherlands
R. Boerman, D. Cohen, A. Nugter*

O-04-003

Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: results from the FACE-SZ data-set
*G. Fond, Creteil, France
O. Godin, P.-M. Llorca, M. Leboyer*

O-04-004

Measures of glucose and lipid metabolism at the fasted state in drug-naïve patients with psychosis; evidence for insulin resistance
*P. Petrikis, Ioannina, Greece
S. Tigas, V. Boumba, A. Tzallas, I. Papadopoulos, P. Skapinakis, T. Vougiouklakis, V. Mavreas*

O-04-005

Inflammatory activity in psychotic disorders after accounting for cardiovascular risk factors
*I. Dieset, Oslo, Norway
E. Reponen, R. Mørch, E. Hoseth, S. Hope, I. Agartz, I. Melle, S. Djurovic, P. Aukrust, T. Ueland, O. Andreassen*

O-04-006

Studying heart arrhythmias in relation to psychosis (SHARP). Increased prevalence of Brugada syndrome in recent onset schizophrenia
A. Sutterland, Amsterdam, The Netherlands

S-34	SYMPOSIA
08:30 – 10:00	Cambridge, 2nd Floor
Gaps in knowledge around and implementation of early intervention for psychosis: setting an agenda for the future	
<i>Chairs: A. Malla, Montreal, Canada</i>	
<i>S. Iyer, Montreal, Canada</i>	

S-34-001

The optimal duration of early intervention services for psychosis: two Canadian studies

A. Malla, Montreal, Canada

R. Joobar, S. Iyer, D. Lutgens, S. Abadi

S-34-002

Transitioning between mental health services: processes, experiences, outcomes and challenges

S. Singh, Coventry, United Kingdom

S-34-003

Lacunae in early psychosis services and research: culture, diversity and context

S. Iyer, Montreal, Canada

H. Loohuis, M. Pope, G. Etienne, G. Mohan, T. Rangaswamy, A. Malla

S-34-004

Addressing the gaps between research and efforts to reduce the stigma of psychosis

R. Norman, London, Canada

S-35	SYMPOSIA
08:30 – 10:00	Oxford, 2nd Floor
Clinical and biological impact of exercise interventions in schizophrenia	
<i>Chairs: P. Falkai, Munich, Germany</i>	
<i>H. Hulshoff Pol, Utrecht, The Netherlands</i>	

S-35-001

Changes in brain connectivity after endurance training in schizophrenia

H. Hulshoff Pol, Utrecht, The Netherlands

A. Svatkova, R. Mandl, T. Scheewe, W. Cahn, R. Kahn

S-35-002

The effects of endurance training on brain structure and function in multi-episode schizophrenia patients and healthy controls

B. Malchow, Munich, Germany

S-35-003

Assessment of physical activity and fitness in early schizophrenia

A. de Herd, Heverlee, Belgium

S-35-004

Vascular plasticity after aerobic exercise in healthy adults

E. Düzel, Magdeburg, Germany

O-05 ORAL PRESENTATIONS

08:30 – 10:00 Harvard, 1st Floor

Alternative treatment approaches

Chair: U. Schall, Callaghan, Australia

O-05-001

The impact of aerobic exercise on brain-derived neurotrophic factor and neurocognition in individuals with schizophrenia: a single-blind, randomized clinical trial

D. Kimhy, New York, USA

O-05-002

Applying anodal tDCS on left lateral prefrontal cortex to enhance computer-assisted cognitive remediation for schizophrenia

G. Di Lorenzo, Rome, Italy

S. Emiliano, D. Serrone, A. Daverio, F. Ferrentino, V. De Lorenzo, C. Di Lorenzo, C. Niolu, S. Seri, S. Rossi, A. Siracusano

O-05-003

Transcranial Direct Current Stimulation (tDCS) improves negative symptoms in schizophrenia: a double-blind, randomized, clinical Trial

A. Hasan, Munich, Germany

U. Palm, D. Keeser, J. Blautzik, N. Sarubin, F. Kaymakonova, I. Unger, M. Kupka, B. Ertl-Wagner, P. Falkai, F. Padberg

O-05-004

Meta analysis of oxytocin in schizophrenia: effects on symptoms and social cognition

A. Macbeth, Edinburgh, United Kingdom

A. Gumley, C. Braehler, M. Schwannauer

O-05-005

m-RESIST project: is it possible to improve the care of treatment-resistant schizophrenia using modern m-health based treatment modalities?

K. Rubinstein, Ramat Gan, Israel

A. Caspi, E. Jääskeläinen, M. Isohanni, J. Usall, E. Huerta-Ramos, U. Zsolt, I. Bitter, S. van der Graaf, M. Hospedales, I. Corripio Collado

O-05-006

Cannabis and schizophrenia – a Cochrane review

J. Pushpa-Rajah, Nottingham, United Kingdom

B. McLoughin, D. Gilles

S-37 SYMPOSIA

08:30 – 10:00 Stanford, 1st Floor

The neurobiology of language related symptoms in schizophrenia

Chairs: W. Strik, Bern, Switzerland

I. Sommer, Utrecht, The Netherlands

S-37-001

The neurobiology of thought disorders in psychosis

T. Kircher, Marburg, Germany

S-37-002

Factors influencing the efficacy of rTMS in the treatment of auditory hallucinations

C. Nathou, Caen, France

S. Dollfus, O. Etard, G. Simon

S-37-003

Language lateralization and language-related symptoms of schizophrenia

I. Sommer, Utrecht, The Netherlands

S-37-004

Network dynamics of the language circuitry during formal thought disorders and hallucinations

W. Strik, Bern, Switzerland

D. Hubl, J. Kindler, P. Homann, T. Dierks, H. Horn

S-38	SYMPOSIA
08:30 – 10:00	Princeton, 1st Floor
Computational approaches to schizophrenia	
<i>Chairs: F. Schlagenhauf, Berlin, Germany</i>	
<i>C. Mathys, London, United Kingdom</i>	

S-38-001

Psychosis as a pathology of belief updating in response to new information – formal foundations and neurobiological perspectives
C. Mathys, London, United Kingdom

S-38-002

Why jump to conclusions, and why stick to them? Computational modelling of the beads task in schizophrenia and schizotypy
R. Adams, London, United Kingdom

S-38-003

Decisions in dynamic environments – behavioral and neural signatures of flexible decision-making in schizophrenia
L. Deserno, Leipzig, Germany

S-38-004

How much does working memory contribute to learning impairments in schizophrenia?
A. Collins, Providence, USA

S-39	SYMPOSIA
10:30 – 12:00	Cambridge, 2nd Floor
Epidemiological and clinical aspects of psychosis risk syndromes and psychotic experiences in children, adolescents and adults	
<i>Chairs: S. Ruhrmann, Cologne, Germany</i>	
<i>F. Schultze-Lutter, Bern, Switzerland</i>	

S-39-001

Prevalence, familial liability and clinical correlates of psychotic experiences and symptoms in children of the general population: the Copenhagen Child Cohort 2000
P. Jeppesen, Glostrup, Denmark
J. T. Larsen, L. Clemmensen, A. Munkholm, M. K. Rimvall, C. U. Rask, J. van Os, L. Petersen, A. M. Skovgaard

S-39-002

Follow-up findings of the Bern Epidemiological At-Risk (BEAR) study
F. Schultze-Lutter, Bern, Switzerland
C. Michel, B. G. Schimmelmann

S-39-003

Age as a source of heterogeneity in psychosis high risk research
S. Ruhrmann, Cologne, Germany
S. Schmidt, F. Schultze-Lutter

S-39-004

Social environment as a risk factor for psychosis proneness
J. Kirkbride, London, United Kingdom
J. Stochl, J. Zimbron, C. Crane, A. Metastasio, E. Aguilar, R. Webster, S. Theegala, N. Kabacs, P. Jones, J. Perez

S-40	SYMPOSIA
10:30 – 12:00	Oxford, 2nd Floor
Current state and perspectives of policies for schizophrenia care	
<i>Chairs: V. Larach, Santiago, Chile</i>	
<i>P. Falkai, Munich, Germany</i>	

S-40-001

Quality assurance in schizophrenia treatment and care: state of the art and policy developments

W. Gaebel, Düsseldorf, Germany

S-40-002

Bridging the gap between neuroscience and policy care in schizophrenia

P. Falkai, Munich, Germany

S-40-003

10 years after a state law government policy care for schizophrenia in an emergent economy. Pros and Cons

V. Larach, Santiago, Chile

L. Varela, G. Vergara, J. Ochoa

S-40-004

Social functioning of persons with schizophrenia living in community: implications for real-life based policies

S. Galderisi, Naples, Italy

S-41	SYMPOSIA
10:30 – 12:00	Harvard, 1st Floor
Evidence for brain stimulation methods in schizophrenia	
<i>Chairs: J. Cordes, Düsseldorf, Germany</i>	
<i>C. Plewnia, Tübingen, Germany</i>	

S-41-001

Effects of transcranial direct current stimulation (tDCS) on executive functions

C. Plewnia, Tübingen, Germany

S-41-002

rTMS for the treatment of negative symptoms in residual schizophrenia

T. Wobrock, Groß-Umstadt, Germany

A. Hasan, J. Cordes, W. Wölwer, B. Langguth, M. Landgrebe, R. Ahmed, W. Gaebel, B. Guse, P. Falkai

S-41-003

The treatment of hallucinations in schizophrenia spectrum disorders

I. Sommer, Utrecht, The Netherlands

S. Schulte-Koops

S-41-004

Predictors of response to electroconvulsive therapy in treatment-resistant schizophrenia

T. Pawelczyk, Lodz, Poland

E. Kołodziej-Kowalska, A. Pawelczyk

S-42	SYMPOSIA
10:30 – 12:00	Stanford, 1st Floor
Dopamine and learning dysfunction in schizophrenia	
<i>Chairs: A. Heinz, Berlin, Germany</i>	
<i>A. Abi-Dargham, New York, USA</i>	

S-42-001

The dopaminergic dual phenotype in schizophrenia

A. Abi-Dargham, New York, USA

S-42-002

Reward-guided learning and dopamine in schizophrenia

F. Schlagenhauf, Berlin, Germany

L. Deserno, A. Heinz

S-42-003

Deficits in predictive coding underlie hallucinations in schizophrenia

G. Horga, New York, USA

S-42-004

Connectivity patterns during working memory define clinically distinct subgroups of schizophrenia

K. E. Stephan, Zurich, Switzerland

O-06	ORAL PRESENTATIONS
10:30 – 12:00	Princeton, 1st Floor
Psychosocial treatment	
<i>Chair: T. Lincoln, Hamburg, Germany</i>	

O-06-001

Psychological treatments for early psychosis can be beneficial or harmful, depending on the therapeutic alliance: an instrumental variables analysis

L. Goldsmith, Manchester, United Kingdom

S. W. Lewis, R. P. Bentall, G. Dunn

O-06-002

Family Motivational Intervention: effectiveness, feasibility and 15 months follow up

R. Keet, Heiloo, The Netherlands

O-06-003

Mindfulness and schizotypy: magical thinking without suspiciousness characterises mindfulness meditators

V. Kumari, London, United Kingdom

E. Antonova, A. Hamid, B. Wright

O-06-004

REFLEX: a metacognitive group treatment to improve insight in psychosis and to reduce self-stigma

M. Pijnenborg, Groningen, The Netherlands

A. de Vos, L. van der Meer, C. Bockting, M. van der Gaag, A. Aleman

O-06-005

Improving functional competence, neurocognition, social cognition and negative symptoms in schizophrenia: randomized controlled trial

J. Peña, Bilbao, Spain

N. Ibarretxe-Bilbao, P. Sanchez, E. Elizagarate, J. Ezcurra, M. Gutierrez, N. Ojeda

O-06-006

Beat victimization! Psychomotor assertiveness training with elements of kickboxing for people with psychotic disorders

E. van der Stouwe, Groningen, The Netherlands

B. de Vries, M. Pijnenborg, J. van Busschbach, A. Aleman

PL-03 **PLENARY LECTURES**

12:15 – 13:00 **B** Cambridge, 2nd Floor

Predictors and mechanisms of conversion to psychosis

Chair: S. Galderisi, Naples, Italy

PL-03-001

Predictors and mechanisms of conversion to psychosis

T. D. Cannon, New Haven, USA

B Broadcasting of Plenary Lecture in room Oxford

P-11 **POSTER SESSIONS**

13:30 – 14:30 Foyer, 2nd Floor

Early stages of schizophrenia

Chair: A. Bechdolf, Berlin, Germany

P-11-001

Why are help-seeking subjects at ultra-high risk for psychosis help-seeking?

I. Falkenberg, Marburg, Germany

L. Valmaggia, M. Byrnes, M. Frascarelli, C. Jones, M. Rocchetti, B. Straube, S. Badger, P. McGuire, P. Fusar-Poli

P-11-002

Patterns of risk status in repeated measures over time: to what degree do they inform about conversion risk?

F. Schultze-Lutter, Bern, Switzerland

S. Ruhrmann, B. G. Schimmelmann, J. Klosterkötter, S. J. Schmidt

P-11-003

Mechanisms of transmission of health and risk in parents with schizophrenia or bipolar disorder and their offspring (The WARM Study)

A. Macbeth, Edinburgh, United Kingdom

K. Davidsen, J.-M. Lundy, K. Røhder, C. Høier Trier, M. Nyström-Hansen, A. Gumley, S. Harder

P-11-004

Mediation models from childhood adversity to depressiveness in patients at-risk for psychosis and in help-seeking controls

F. Schultze-Lutter, Bern, Switzerland

S. Ruhrmann, B. G. Schimmelmann, J. Klosterkötter, S. J. Schmidt

P-11-005

Insecure attachment styles as mediators between poor childhood care and schizophrenia-spectrum phenomenology: an interview study

T. Sheinbaum, Barcelona, Spain

A. Bifulco, S. Ballespi, M. Mitjavila, T. R. Kwapił, N. Barrantes-Vidal

P-11-006

Association of early psychosis patients' and relatives' attachment style with clinical and functional presentation

L. Hinojosa-Marqués, Barcelona, Spain

T. Sheinbaum, P. Cristóbal-Narváez, M. Monsonet, T. R. Kwapił, T. Domínguez-Martínez, N. Barrantes-Vidal

P-11-007

Attention hyperactivity phenotype in children and adolescents offspring of schizophrenia and bipolar disorder: a controlled study

V. Sanchez-Gistau, Barcelona, Spain

S. Romero, E. de la Serna, G. Sugranyes, I. Baeza, D. Moreno, E. Rodríguez, C. Moreno, J. Castro-Fornieles

P-11-008

Associations of different measures and facets of self-esteem with paranoia in early psychosis

M. Monsonet, Bellaterra, Spain

P. Cristóbal-Narváez, T. Sheinbaum, T. Domínguez-Martínez, T. R. Kwapił, B.-V. Neus

P-11-009

Positive and negative schizotypy prediction of prodromal symptoms and schizophrenia-spectrum personality disorder traits: a 3-year prospective study

A. Racioppi, Barcelona, Spain

T. Sheinbaum, S. Ballespi, M. Mitjavila, G. M. Gross, T. R. Kwapil, N. Barrantes-Vidal

P-11-010

Symptoms severity at admission is related to insight at discharge in first episode of psychosis

J. L. Fernandez Gonzalez, Ubeda, Spain

A. Lopez Diaz, I. Lara Ruiz-Granados

P-11-011

Predicting depressive symptoms in a recent onset psychosis patient

A. Guasp Tortajada, Valencia, Spain

S. M. Study Group, E. Lorente-Rovira, A. Luengo, B. Llacer, J. M. Carot, J. Sanjuan

P-11-012

12 months follow-up of a child and adolescent sample at risk for psychosis

M. Dalz, Barcelona, Spain

J. Tor, M. Pardo, D. Muñoz, E. De la Serna, V. Sánchez-Guistau, J. Álvarez, G. Sugranyes, I. Baeza

P-12

POSTER SESSIONS

13:30 – 14:30

Event Area, Ground Floor

Comorbidity

Chair: J. Seppälä, Oulu, Finland

P-12-001

Schizophrenia and left eye maculopathy

E. Neroutsos, Magoula Elefsina, Greece

S. Foteli, M. Fiste, A. Zachariadis

P-12-002

Oral health in persons with psychosis: a population-based study

K. Partti, Helsinki, Finland

L. Suominen, J. Perälä, S. Saarni, M. Vehkalahti, M. Knuuttila, J. Lönnqvist, J. Suvisaari

P-12-003

Clinical-dynamic characteristics of schizophrenia in patients of the somatic network

V. Lebedeva, Tomsk, Russia

A. Semke, E. Yurovskaya

P-12-004

First episode of schizophrenia is characterized by pronounced metabolic disturbances

M. Uzbekov, Moscow, Russia

E. Misionzhnik, A. Shmukler, N. Smolina, T. Syrejschikova, S. Shikhov

P-12-005

Comorbid intellectual disability in a schizophrenic framework: case report

C. Bonadio, São Paulo, Brazil

B. Tasso, J. Maldos

P-12-006

Possible predictors and consequences of alcohol abuse in schizophrenic patients

S. Djordjevic, Kovin, Serbia

S. Kijac, D. Kernican

P-12-007

Pattern and prevalence of psychiatric consultations in other non-psychiatric in-patient facilities in the University of Port Harcourt Teaching Hospital (UPTH): a 5-year review

A. K. Nkporbu, Port Harcourt, Nigeria

L. O. Ugboma, P. C. Stanley

P-12-008

Socio-demographic and clinical determinants of psychiatric co-morbidity in persons with essential hypertension attending the university of Port Harcourt Teaching Hospital

A. K. Nkporbu, Port Harcourt, Nigeria

G. Eze, P. C. Stanley

P-12-009

Association of severity of essential hypertension and psychiatric co-morbidity in patients attending the cardiovascular out-patients clinic in University of Port Harcourt Teaching Hospital (UPTH)

A. K. Nkporbu, Port Harcourt, Nigeria

P. C. Stanley

P-13	POSTER SESSIONS
13:30 – 14:30	Sorbonne 2, 2nd Floor
Drug and somatic treatment II	
<i>Chair: L. Wunderink, Groningen, The Netherlands (tbc)</i>	

P-13-001

Epidemiological study for the analysis of satisfaction and treatment preferences in schizophrenia (PREFERE study)

B. Herrera Alvarado, Madrid, Spain

M. Bernardo, F. Cañas

P-13-002

Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset

G. Fond, Creteil, France

L. Boyer, M. Favez, P.-M. Llorca, A. Pelissolo

P-13-003

Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset

F. Berna, Strasbourg, France

G. Fond, L. Boyer, D. Misdragi, P.-M. Llorca

P-13-004

Symptoms severity as a predictor of antipsychotic maintenance dose in first episode psychosis

J. L. Fernandez Gonzalez, Ubeda, Spain

A. Lopez Diaz, I. Lara Ruiz-Granados

P-13-005

Evidenced based clinical practice guideline and psychopharmacological tools for homeless adults with schizophrenia and co-occurring alcohol use disorder

J. Cotton, Brooklyn, USA

M. Potter, J. Bouchard-Burns

P-13-006

Omega 3 fatty acids supplementation in schizophrenia

C. Palma, Mataro, Spain

J. Cañete Crespillo, L. Montesinos

P-13-007

High-frequency repetitive transcranial magnetic stimulation for treatment-refractory auditory hallucinations in schizophrenia: a double-blind randomized sham-controlled trial

N. Kanahara, Chiba City, Japan

H. Kimura, M. Takase, T. Yoshida, H. Watanabe, M. Iyo

P-13-008

Neurorehabilitation in schizophrenia

G. N. Jemar, Caba, Argentina

G. Bartoli

P-13-009

Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study

B. Joffe, New York, USA

R. Joffe, C. Correll, L. Rosen, T. Sullivan

P-13-010

Effectiveness of neuroleptic and antidepressant therapy in schizoaffective disorders, depressive type

Z. Mitic, Skopje, Republic of Macedonia

A. Spasovska

P-13-011

Effectiveness of neuroleptic therapy in methadone maintenance patients with psychotic disorders

A. Spasovska, Skopje, Republic of Macedonia

Z. Mitic

P-14 POSTER SESSIONS

13:30 – 14:30 Event Area, Ground Floor

Psychophysiology

Chair: P. Uhlhaas, Glasgow, United Kingdom

P-14-001

Reaction time, processing speed, sustained attention in patients with schizophrenia: relationship with symptoms and treatment

G. Lahera, Madrid, Spain

A. Orozco, A. Brañas, M. Vicens, A. Ruiz, M. Sillero

P-14-002

Deficits in agency in schizophrenia, and additional deficits in body image, body schema and internal timing, in passivity symptoms

K. Graham-Schmidt, Crawley, Australia

M. Martin-Iverson, N. Holmes, A. Jablensky, F. Waters

P-14-003

Access to body structural description is impaired in schizophrenia and coincides with alterations in body image that worsen with passivity symptoms

K. Graham-Schmidt, Crawley, Australia

M. Martin-Iverson, N. Holmes, F. Waters

P-14-004

Increased interpersonal distance in schizophrenia patients with prominent paranoid symptoms

G. Schoretsanitis, Bern, Switzerland

A. Kutynia, S. Walther, W. Strik

P-14-005

Electrophysiological investigation of reward anticipation and negative symptoms in schizophrenia

V. Montefusco, Naples, Italy

A. Vignapiano, A. Mucci, E. Merlotti, G. M. Plescia,

O. Gallo, G. M. Giordano, M. Rocco, P. Romano,

S. Galderisi

P-14-006

Early auditory event-related potentials and poor functioning in real-life: an electrophysiological study in patients with schizophrenia

G. M. Plescia, Naples, Italy

A. Vignapiano, E. Merlotti, A. Mucci, G. Di Lorenzo,

A. Daverio, M. Ribolsi, C. Nioiu, V. Montefusco, P. Romano, S. Galderisi

P-14-007

Do reward-processing deficits in schizophrenia promote cannabis use? An investigation of physiological and behavioral responses to natural rewards and drug cues

C. Cassidy, New York, USA

M. Brodeur, M. Lepage, A. Malla

P-14-008

Neurophysiological correlate of mental workload in psychotic patients: is there a specific pattern?

G. Favre, Fribourg, Switzerland

S. Horat, P. Missonnier, F. Herrmann, M. Merlo

P-14-010

Decreased heart rate variability in schizophrenia – a meta-analysis

A. Clamor, Hamburg, Germany

T. M. Lincoln, J. F. Thayer, J. Koenig

P-14-011

Modulation of auditory steady-state responses in schizophrenia: eyes closed vs. eyes open

K. Dapsys, Vilnius, Lithuania

S. Melynyte, A. Voicikas, A. Siurkute, V. Maciulis,

I. Griskova-Bulanova

P-14-012

Small saccades during free viewing of natural images in schizophrenia: a new perspective

R. Mayol, Santiago, Chile

J. I. Egaña, C. Devia, J. Parrini, G. Orellana, A. Ruiz,

P. Maldonado

P-14-013

Neurophysiological markers of auditory pseudo-hallucinatory

A. Arkhipov, Moscow, Russia

A. Maslennikova, V. Strelets

P-14-014

P100 and N170 of the verbal informational processing in norm and in schizophrenia

V. Strelets, Moscow, Russia

P-15 POSTER SESSIONS

13:30 – 14:30 Event Area, Ground Floor

Neuroimaging II

Chair: A. Mucci, Naples, Italy

P-15-001

Using a novel diffusion magnetic resonance imaging method to investigate microstructural gray matter changes in schizophrenia

J. Seitz, Boston, USA

Y. Rathj, A. Lyall, O. Pasternak, E. del Re, M. Shenton,

I. Koerte, M. Kubicki

P-15-002

Gray matter changes in Japanese subjects with ultra-high risk for psychosis and patients with first-episode psychosis

K. Abe, Sendai, Japan

A. Sakuma, T. Obara, M. Katsura, K. Iidsuka, T. Kikuti,

K. Kokubun, N. Ohmuro, H. Matsuoka, K. Matsumoto

P-15-003

The neuropathological study of Myeline-Oligo-dendrocyte in postmortem schizophrenic brain

T. Marui, Nagoya, Japan

Y. Torii, S. Iritani, S. Morosawa, K. Oshima, K. Niizato,

K. Masaki, J. Kira, H. Fujishiro, N. Ozaki

P-15-004

White matter correlates of the DSM-5 schizophrenia symptom dimensions

P. Viher, Bern, Switzerland

K. Stegmayer, A. Federspiel, B. Stephan, R. Wiest,

W. Strik, S. Walther

P-15-005

Identifying apathy in schizophrenia based on structural neuroanatomical differences

E. Opmeer, Groningen, The Netherlands

M.-J. van Tol, E. Liemburg, H. Knegtering, G. Pijnenborg,

R. Renken, A. Aleman

P-15-006

Disrupted thalamo-frontal white matter connectivity in patients with schizotypal personality disorder

T. Y. Lee, Seoul, Republic of Korea

P-15-007

Altered thalamo-cortical white matter connectivity: probabilistic tractography study in clinical – high risk for psychosis and first episode psychosis

K. I. Cho, Seoul, Republic of Korea

M. Shenton, M. Kubicki, W. H. Jung, T. Y. Lee, J.-Y. Yun,

S. N. Kim, J. S. Kwon

P-15-008

Spectroscopy differences between at risk populations for psychosis

O. Bloemen, Hilversum, The Netherlands

C. Vingerhoets, G. Bakker, E. Boot, F. da Silva Alves,

T. van Amelsvoort

P-15-009

Impairment in social cognition in schizophrenia is associated to early neurodevelopmental deviations of the Anterior Cingulate Cortex

V. Marzloff, Caen, France

S. Dollfus, P. Brazo, M.-O. Krebs, A. Cachia

P-15-010

Aberrant lateralization pattern of resting state brain in schizophrenia

S. N. Kim, Seoul, Republic of Korea

H. J. Jo, J. H. Jang, T. Y. Lee, J. S. Kwon

P-15-011

Auditory verbal hallucinations and glutamate in prefrontal cortex of patients with psychotic disorders

L. Bais, Groningen, The Netherlands

B. Curcic-Blake, M. Pijnenborg, E. Liemburg, A. Aleman

S-43	SYMPOSIA
14:30 – 16:00	Oxford, 2nd Floor
Cycloid psychoses and chronic schizophrenia: clinical profiles and the role of CNVs	
<i>Chairs: G. Stöber, Würzburg, Germany</i>	
<i>G. Kirov, Cardiff, United Kingdom</i>	

S-43-001

Cycloid psychoses: psychopathological profile in a clinical setting and biochemical differences

N. van der Kerkhof, Venray, The Netherlands

D. Fekkes, F. Van der Heijden, M. Schneider, W. Verhoeven

S-43-002

Clinical outcome in cycloid psychoses vs manic depressive illness: a 12-year follow-up study

B. Pfuhlmann, Dresden, Germany

S-43-003

Genome-wide analysis of CNVs in cycloid psychoses and chronic schizophrenia, including phenotype-correlation und functional pathway-analysis

M. Gawlik, Würzburg, Germany

G. Kirov, G. Stöber

S-43-004

The penetrance of CNVs for schizophrenia and other neurodevelopmental disorders

G. Kirov, Cardiff, United Kingdom

S-44	SYMPOSIA
14:30 – 16:00	Harvard, 1st Floor
Bridging the gap between treatment engagement and treatment outcomes	
<i>Chairs: N. Mulder, Rotterdam, The Netherlands</i>	
<i>E. Jochems, Rotterdam, The Netherlands</i>	

S-44-001

Meta-analysis of interventions to improve adherence to antipsychotic medications in patients with psychotic disorders

N. Mulder, Rotterdam, The Netherlands

A. Staring, E. Noordraven, W. Bramer, M. van der Gaag

S-44-002

MotivaTe-IT: motivation for treatment as a bridge to treatment engagement and outcomes?

E. Jochems, Rotterdam, The Netherlands

C. van der Feltz-Cornelis, A. van Dam, H. Duivenvoorden, N. Mulder

S-44-003

Money for medication: money as a bridge to treatment engagement and outcomes?

E. Noordraven, Rotterdam, The Netherlands

N. Mulder

S-44-004

Acemap, a long acting oral antipsychotic agent as a way of improving treatment engagement and outcomes?

J. Gilden, Rotterdam, The Netherlands

A. I. Wierdsma, J. M. van Beveren, L. Hakkaart, R. van Westrhenen, C. M. van der Feltz-Cornelis, L. de Haan, C. L. Mulder

S-45	SYMPOSIA
14:30 – 16:00	Stanford, 1st Floor
Abnormalities of motor function in neuropsychiatric disorders: a transdiagnostic approach	
<i>Chairs: D. Hirjak, Heidelberg, Germany</i>	
<i>C. Wolf, Homburg, Germany</i>	

S-45-001

Neural mechanisms of catatonia

C. Wolf, Homburg, Germany

S-45-002

Neuroanatomical signature of neurological soft signs in recent-onset schizophrenia and Asperger-Syndrome

D. Hirjak, Heidelberg, Germany

S-45-003

Shall we do this together? The influence of social gaze on mechanisms of action control in healthy controls and adult individuals with high-functioning autism

L. Schilbach, Cologne, Germany

S-45-004

Structural imaging correlates of motor impairments in schizophrenia – gesture control and motor slowing

S. Walther, Bern, Switzerland

P. Viher, T. Bracht, W. Strik, A. Federspiel, R. Wiest, S. Bohlhalter, K. Stegmayer

O-07	ORAL PRESENTATIONS
14:30 – 16:00	Princeton, 1st Floor
Neuropsychology	
<i>Chair: W. Wölwer, Düsseldorf, Germany</i>	

O-07-001

Verbal memory and the primary/secondary negative symptoms distinction following a first episode of psychosis

M. Lepage, Verdun, Canada

M. Bodnar, R. Joobar, A. Malla

O-07-002

Facial emotion identification in first-episode psychosis: severity and pattern of impairment differs for schizophrenia versus affective psychoses

S. Barkl, Sydney, Australia

A. Harris, L. Williams, A. Brennan, C. Gott, S. Lah

O-07-003

Neurocognitive deficits according to norms in adolescents with and without clinical high risk states of psychosis

C. Michel, Bern, Switzerland

B. G. Schimmelmann, A. Martz-Irngartinger, P. Walger, M. Franscini, F. Schultze-Lutter

O-07-004

Jumping to conclusions in first episode psychosis

A. Catalan Alcantara, Leioa, Spain

V. Angosto, F. Aguirregomescorta, C. Valverde, S. Bustamante, A. Madrazo, A. Fernandez, M. Gonzalez de Artaza, M. A. Gonzalez-Torres

O-07-005

When one's sense of agency goes wrong: overall decreased estimation of intervals and absent intentional binding in passivity symptoms of schizophrenia

K. Graham-Schmidt, Crawley, Australia

M. Martin-Iverson, N. Holmes, F. Waters

O-07-006

Environmental noise effects on emotional stroop interference in schizophrenia

B. Wright, London, United Kingdom

E. Peters, B. Wright, D. Osborne, V. Kumari

CONFERENCE INFORMATION

CONFERENCE VENUE

Seminaris Science & Conference Center
The Dahlem Cube
Takustraße 39, 14195 Berlin, Germany
www.seminaris.de/hotels/seminaris-campusotel-berlin.html

CONFERENCE REGISTRATION COUNTER

All conference material and documentation are available at the conference registration counter located in the foyer on the ground floor of the Dahlem Cube.

OPENING HOURS

Thursday, 24 Sept. 2015	08:00 – 18:00
Friday, 25 Sept. 2015	08:00 – 18:30
Saturday, 26 Sept. 2015	08:00 – 16:00

During these opening hours the conference counter can be reached at: Phone: +49 – 30 – 557 797 470

REGISTRATION FEE

ON-SITE REGISTRATION

Members of ESAS	EUR 500
Non-members	EUR 570
Trainees *	EUR 470

* Non-tenured junior scientists or clinical residents in training under 35 years (to be confirmed by head of department).

ON-SITE REGISTRATION

On-site registration will be processed on a first-come, first-served basis. Priority will be given to pre-registered delegates. Depending on the number of on-site registered delegates, availability of conference documentation may be limited.

NAME BADGES

Participants are kindly requested to wear their name badge at all times during the conference

including the Opening Ceremony and Networking Reception.

CONFERENCE LANGUAGE

The conference language is English. Simultaneous translation will not be provided.

PROGRAMME CHANGES

The organisers cannot assume liability for any changes in the conference programme due to external or unforeseen circumstances.

ABSTRACT BOOK

All accepted abstracts are published in an abstract book as a supplement of the European Archives of Psychiatry and Clinical Neurosciences (EAPCN). The abstract book is inserted in your conference bag and will be handed out together with the conference documentation at the registration counter.

MEDIA CHECK

The Media Check is located in room Yale 1 on the first floor of the Dahlem Cube. Speakers are asked to hand in their CD ROM or USB stick, containing the PowerPoint presentation (IBM format or compatible, no multisession) preferably one day before their session but at the latest 90 minutes prior to the presentation. The presentation will be transferred to a special conference notebook in the session room. Due to time and technical reasons we kindly ask the speakers not to use their own notebook.

OPENING HOURS

Thursday, 24 Sept. 2015	08:00 – 18:00
Friday, 25 Sept. 2015	08:00 – 18:30
Saturday, 26 Sept. 2015	08:00 – 15:00

POSTER EXHIBITION

Posters are grouped according to related topics and are on display in three different areas: in the event area on the ground floor and on the second floor in Sorbonne 2 as well as in the related foyer. Please see the poster plan on page 58.

Posters will be on display for the entire time of the conference. They will be sorted by topics and will be numbered within those topics.

The poster exhibition is open to all registered delegates. Senior scientists will guide the daily tours of poster board presentations.

Thursday, 24 Sept. 2015

Guided Poster Tours P-01 – P-05: 13:30 – 14:30

Friday, 25 Sept. 2015

Guided Poster Tours P-06 – P-10: 13:30 – 14:30

Saturday, 26 Sept. 2015

Guided Poster Tours P-11 – P-15: 13:30 – 14:30

Interested participants can meet the authors for discussions of their poster presentation during the time of the poster tour.

Set-up and dismantling times for posters

Set-up:

Thursday, 24 Sept. 2015: 08:00 – 10:00

Dismantling:

Saturday, 26 Sept. 2015: 16:00 – 17:00

Posters which have not been removed within the indicated dismantling time will be disposed.

CERTIFICATE OF ATTENDANCE

A certificate of attendance will be handed out upon demand at the registration counter.

COFFEE BREAKS

Coffee, tea and mineral water will be served free of charge to all registered delegates during the morning and afternoon coffee breaks from Thursday, 24 September, to Saturday, 26 September 2015. Coffee bar stations are located in the foyer areas of the ground floor. In addition to the regular coffee breaks the coffee bar on the first floor will provide drinks on cash basis.

LUNCH AND RESTAURANTS

A lunch snack will be served to all registered delegates during the lunch breaks from Thursday, 24 September, to Saturday, 26 September 2015, in the foyer of the ground floor. The conference venue further provides a restaurant in the Seminaris hotel opposite the courtyard of the Dahlem Cube where snacks and food are available on cash basis.

MOBILE PHONES

Participants are kindly requested to keep their mobile phones turned off while attending the scientific sessions.

INSURANCE

The conference fee does not include insurance. All participants are advised to arrange for their own insurance. Health and accident insurance is recommended and has to be purchased in your country of residence.

HOW TO GET TO THE SEMINARIS CAMPUS HOTEL



By car:

From the North: A 115 southward, AS 2 Hüttenweg direction city, turn left Clayallee, right into Königin-Luise-Straße, right into Takustraße/Lansstraße

From the West: A2/A 10/A 115 direction Potsdam/Berlin/AS 4 Zehlendorf/B1 Potsdamer Chaussee/turn left Clayallee/right Königin-Luise-Straße/right into Takustraße/Lansstraße

From the South: via A 103/AS 5 Schlossstraße to the B1, Unter den Eichen, turn right into Fabekstraße then Lansstraße

From the East: via A 12/A 10/A 113 direction airport BBI (Schönefeld)/A 100/A 103/exit 5 Wolfensteindamm, turn right into Schlossstraße direction Dahlem/left into Grunewaldstraße/Königin-Luise-Straße/Lansstraße

Distance to the airport:

Berlin Tegel: Transfer time by taxi approximately 30 minutes depending on traffic

Berlin Schönefeld: Transfer time by taxi approximately 45 minutes depending on traffic

By train:

Berlin main station (ICE, IC-, RE- und RB-Station), then take the underground U3 to station "Dahlem-Dorf". Exit the station towards Königin-Luise-Straße. Follow the road for 300 m until you reach the crossroad Takustraße.


City hotels Kurfürstendamm:

Point of departure: Heidelberger Platz

Take the underground U3 to Krumme Lanke and get off at Dahlem-Dorf towards direction Königin-Luise-Straße. From here 300 m walk to the Seminaris Campushotel.

PARKING

There is an underground car park with direct access to the Seminaris Campus Hotel. The parking fee is 2 Euros per hour and 12 Euros per night.



Advances in Biological Psychiatry, Vol. 29

Proteomics and Metabolomics in Psychiatry

Editor: Martins-de-Souza, D. (Campinas/Munich)

VIII + 42 p., 9 fig., 1 in color, 10 tab., 2014
CHF 92.00 / EUR 77.00 / USD 108.00
(hard cover)

ISBN 978-3-318-02599-6

e-ISBN 978-3-318-02600-9

Prices subject to change, VAT not included
EUR price for eurozone countries,
USD price for USA and Latin America only



The easiest way to order:

www.karger.com/adbip

Proteomics and Metabolomics in Psychiatry

Editor:

Martins-de-Souza, D. (Campinas/Munich)

CONTENTS

• Preface

Schizophrenia and Psychotic Disorders


- Proteomic Characterization of the Brain and Cerebrospinal Fluid of Schizophrenia Patients: *Café-Mendes, C.C.; Gattaz, W.F.; Schmitt, A.; Britto, L.R.G.; Martins-de-Souza, D.*
- Peripheral Biomarker Candidates in Schizophrenia: *Thome, J.; Bratek, A.; Krysta, K.*
- Schizophrenia: Blood-Serum-Plasma Metabolomics: *Lista, S.; Giegling, I.; Rujescu, D.*
- Proteomic and Metabolomic Evidence for Glial Alterations in Schizophrenia: *Beasley, C.L.; Barakauskas, V.E.*
- Insights from Proteomic Studies on Schizophrenia Preclinical Models: What Can We Learn for Drug Discovery? *Farrelly, L.A.; Föcking, M.; Cotter, D.R.*
- Metabolomics to Study Psychotic Disorders and Their Metabolic Comorbidities: *Orešič, M.*

Mood Disorders


- Peripheral Biomarkers for Depression by Plasma and Serum Proteomics: *Domenici, E.*
- Proteomics of Preclinical Models of Depression: *Carboni, L.*
- Antidepressant Response Metabonomics: *Quin, X.*
- Proteomics and Metabolomics of Bipolar Disorder: *Sussulini, A.*
- Use of Metabolomics and Proteomics to Reveal Pathophysiological Pathways in Anxiety Disorders: *Altmaier, E.; Emeny, R.T.*

FLOORPLAN


GROUND FLOOR



FIRST FLOOR



SECOND FLOOR



ACKNOWLEDGEMENTS/FUNDINGS

This conference will be completely independent from industry funding.


The Organisers of this conference gratefully acknowledge the support of the German Research Association (DFG)




POSTER AREAS

Poster sessions are grouped according to related topics and are on display in three different areas.

GROUND FLOOR, EVENT AREA



SECOND FLOOR, FOYER AND SORBONNE 2



GUIDED POSTER TOURS: 13:30 –14:30

Thursday, 24 September 2015

P-01	Epidemiology and health services research
P-02	Diagnosis and classification
P-03	Drug and somatic treatment I
P-04	Neuropsychology I
P-05	Genes and gene-environment interaction

Friday, 25 September 2015

P-06	Neurobiology and animal models
P-07	Outcome
P-08	Psychosocial factors and interventions
P-09	Neuropsychology II
P-10	Neuroimaging I

Saturday, 26 September 2015

P-11	Early stages of schizophrenia
P-12	Comorbidity
P-13	Drug and somatic treatment II
P-14	Psychophysiology
P-15	Neuroimaging II

SET-UP AND DISMANTLING TIMES FOR POSTERS

Set-up:

Thursday, 24 Sept. 2015: 08:00 – 10:00

Dismantling:

Saturday, 26 Sept. 2015: 16:00 – 17:00

INDEX OF CHAIRPERSONS, AUTHORS AND PRESENTERS

A

Aas, M.	18
Abe, K.	49
Abi-Dargham, A.	20, 44
Adams, R.	42
Addington, D.	18, 22
Albacete, À.	16
Aleman, A.	19, 23
Allen, P.	19
Alptekin, K.	29
Alvarez Garcia, R.	15
Angosto, V.	31
Antonova, E.	44
Arkipov, A.	48
Ascone Michelis, L.	30
Awad, A. G.	29, 37

B

Bais, L.	49
Bajouco, M.	14
Barkl, S.	51
Bartholomeusz, C. F.	38
Bechdorf, A.	10, 34, 35, 45
Bechter, K.	20, 28
Becker, H.	29
Benros, M.	20
Berg, A. O.	34
Berna, F.	47
Bittner, R.	32
Bloemen, O.	49
Bocharova, A.	17
Boerman, R.	39
Bogers, J.	15, 24
Bogojevic, G.	37
Bonadio, C.	14, 46
Bonivento, C.	37
Borgwardt, S.	19
Brañas, A.	29
Brosda, J.	28
Bruggeman, R.	14
Brunelin, J.	23
Bull, H.	29
Burckhardt, K.	14

C

Cañete Crespillo, J.	30
Cannon, T. D.	45
Cassidy, C.	19, 48
Castilho, P.	30
Catalan Alcantara, A.	51
Chee, I. S.	31
Chieffi, M.	16
Cho, K. I.	49
Christiani, C. A. Jerlang	16
Chung, Y.	13
Clamor, A.	48
Cohen, D.	24
Collins, A.	42
Contreras, F.	16
Cordes, J.	43
Correll, C. U.	24
Cotton, J.	47
Cristóbal-Narváez, P.	17

D

Dammering, F.	31
Dapsys, K.	48
Dean, D.	26, 31
Debbané, M.	11, 34
de Bont, P.	26
de Castro-Catala, M.	17
Degenhardt, F.	17
de Herd, A.	40
Del Pino Saez, R.	31
Depping, M.	12
Deserno, L.	42
de Vos, A.	32
Dierks, T.	23
Dieset, I.	39
Di Lorenzo, G.	41
Djordjevic, S.	46
Dolz, M.	46
Dorofeikova, M.	16
Düzel, E.	40

E

Ehrenreich, H.	17, 20
---------------------	--------

Engel, M.	36
Englisch, S.	24
Espinosa, P. P.	29
Evensen, S.	13

F

Faerden, A.	36
Falkai, P.	35, 40, 43
Falkenberg, I.	45
Fattakhov, N.	17
Favre, G.	48
Fernandez Gonzalez, J. L.	46, 47
Fernandez Miranda, J. J.	29
Fond, G.	27, 28, 39, 47
Freeman, D.	31, 36
Fuglsang Bliksted, V.	38
Fukuda, Y.	32
Fusaroli, R.	38

G

Gaebel, W.	10, 18, 27, 33, 43
Galderisi, S.	25, 33, 43, 45
Gallinat, J.	18
García González, L.	15
Gardsjord, E. S.	18
Gawlik, M.	50
Gil-Ad, I.	28
Gilden, J.	50
Ginsel, S.	30
Goldsmith, L.	44
González-Barroso, A.	31
González-Torres, M.	21
Gorna, K.	29
Graham-Schmidt, K.	48, 51
Guasp Tortajada, A.	46
Gutkevich, E.	30

H

Haenschel, C.	25
Hamdi, G.	14
Hardy, A.	26
Hasan, A.	23, 41
Heinz, A.	33, 44

INDEX OF CHAIRPERSONS, AUTHORS AND PRESENTERS

Heinze Martin, G.	39	Kirkbride, J.	42	Michel, C.	13, 14, 22, 29, 51
Hemager, N.	31	Kirov, G.	50	Michie, P.	25
Herrera Alvarado, B.	47	Klaasen, N.	32	Miettunen, J.	39
Hinojosa-Marqués, L.	45	Klingberg, S.	35	Misdrahi, D.	37
Hirjak, D.	51	Kölkebeck, K.	38	Mitic, Z.	47
Homan, P.	23	Koponen, H.	33	Mittal, V.	26
Hong, E.	25	Kos, C.	32	Moghaddam, B.	20
Horga, G.	44	Koutsouleris, N.	33, 37	Mohnke, S.	19
Hosakova, K.	16	Kumari, V.	19, 32, 44	Mohr, C.	34
Howes, O.	10	Kupper, Z.	12	Möller, H.-J.	27, 33
Hugdahl, K.	18			Monsonet, M.	45
Huguelet, P.	29	L		Montefusco, V.	48
Hulshoff Pol, H.	40	Lahera, G.	21, 48	Mørch-Johnsen, L.	23
Humpston, C.	31	Lambert, M.	36	Morosawa, S.	28
Husa, A.	33	Larach, V.	14, 43	Mucci, A.	38, 49
I		Lasalvia, A.	27	Mulder, N.	50
Ibarretxe-Bilbao, N.	44	Laviolette, S.	20	Mulert, C.	18
Ikemoto, K.	28	Lebedeva, V.	46	Mutica, M.	16
Inta, D.	39	Lee, T. Y.	49		
Ising, H. K.	10	Lenz, C.	37	N	
Isohanni, M.	13, 15, 33	Lepage, M.	51	Najjar, S.	20
Iyer, S.	22, 40	Levinsson, A.	13	Nathou, C.	41
J		Lincoln, T.	11, 24, 36, 44	Neill, J.	38
Jäger, M.	14	Listunova, O.	16	Nerhus, M.	34
Jaya, E.	30	Lorente-Rovira, E.	30	Neroutsos, E.	13, 14, 46
Jemar, G. N.	47	Lyne, J. P.	11, 36	Nkporbu, A. K.	46
Jeppesen, P.	42	Lystad, J.	31	Noordraven, E.	50
Jochems, E.	50	M		Norman, R.	40
Joffe, B.	47	Macbeth, A.	13, 22, 41, 45	O	
K		Malchow, B.	35, 40	Ojeda, N.	30
Kaiser, S.	11, 23	Malla, A.	40	Opmeer, E.	49
Kaltenboeck, A.	31	Martins-de-Souza, D.	35	O'Tuathaigh, C.	38
Kaminski, J.	32	Martins, M. J.	14, 30	Ovejero Garcia, S.	15
Kanahara, N.	47	Marui, T.	49		
Kasperek, T.	19	Marzloff, V.	36, 49	P	
Katthagen, T.	19, 32	Mata Iturralde, L.	13	Palchikov, V.	28
Keet, R.	44	Mathys, C.	42	Palma, C.	47
Kimhy, D.	41	Mayer, J.	32	Palm, U.	41
Kim, S. N.	49	Mayol, R.	48	Palumbo, D.	30
Kircher, T.	26, 32, 41	Melle, I.	13, 18, 25, 34	Pantelis, K.	31
		Mentzel, C.	13	Papassotiropoulos, A.	19
		Mentzel, T.	14, 37	Papsuev, O.	30

Pardo Gallego, M. 13
 Partti, K. 46
 Pawelczyk, T. 17, 43
 Peña, E. 17
 Peña, J. 31, 44
 Petrikis, P. 39
 Pfuhmann, B. 50
 Pijnenborg, M. 44
 Pirlog, M. C. 15
 Plescia, G. M. 48
 Plewnia, C. 23, 43
 Priebe, S. 27
 Pushpa-Rajah, J. 41

R

Rabinowitz, J. 27
 Racioppi, A. 46
 Renard, J. 28
 Riehle, M. 11
 Ripke, S. 27
 Rizos, E. 17
 Rodriguez Blanco, L. 31
 Romm, K. L. 18
 Rössberg, J. I. 18
 Rubinstein, K. 41
 Ruhrmann, S. 22, 37, 42
 Ruiz, J. C. 16
 Rujescu, D. 24
 Rybakowski, J. K. 25, 29, 37

S

Salokangas, R. K. R. 37
 Salvatore, G. 21
 Samimi Ardestani, S. M. 29
 Sánchez Alonso, S. 15
 Sanchez-Gistau, V. 45
 Sapara, A. 32
 Schall, U. 19, 41
 Schennach, R. 24
 Schilbach, L. 51
 Schlagenhauf, F. 11, 23,
 33, 36, 42, 44
 Schmidt, A. 19

Schmitt, A. 35, 39
 Schoretsanitis, G. 48
 Schott, B. 32
 Schulte, P. 15, 24, 37, 39
 Schultze-Lutter, F. 11, 22, 34,
 42, 45

Sedgwick, O. 29
 Seitz, J. 49
 Semenova, N. 30
 Seppälä, J. 33, 46
 Sheinbaum, T. 17, 34, 45
 Sigurdsson, T. 21
 Simonsen, C. 18
 Singh, S. 22, 40
 Smeland, O. B. 17
 Sommer, I. 27, 41, 43
 Spasovska, A. 47
 Spellmann, I. 24
 Stäblein, M. 16
 Stain, H. J. 10
 Stegmayer, K. 36
 Steinau, S. 14
 Steiner, J. 35
 Stephan, K. E. 21, 44
 Sterzer, P. 21
 Steullet, P. 20
 Stiekema, A. 14
 Stöber, G. 50
 Stouten, L. 34
 Straube, B. 26
 Strelets, V. 48
 Strik, W. 18, 33, 36, 41
 Sutherland, A. 27, 39

T

Takase, M. 17
 Tessier, A. 37
 Thomann, P. 12
 Tor, J. 16
 Treen, D. 31

U

Üçök, A. 25, 37

Uhlhaas, P. 11, 21, 25, 48
 Ullevoldsæter, E. 13
 Uzbay, T. 28
 Uzbekov, M. 15, 28, 46

V

van den Berg, D. 26
 van der Gaag, M. 10, 26, 30, 35
 van der Kerkhof, N. 28, 50
 van der Stouwe, E. 44
 van der Vleugel, B. 26
 van Dijk, D. 24
 van Harten, P. 12
 Vaskinn, A. 16
 Verhoeven, W. 17
 Viher, P. 49
 von Wilmsdorff, M. 39

W

Waltereit, R. 39
 Walther, S. 12, 16, 26, 38, 51
 Wehr, M. 28
 Willems, A. 12
 Wobrock, T. 43
 Wolf, C. 12, 51
 Wölwer, W. 21, 35, 51
 Wood, S. 11, 37
 Wotruba, D. 19
 Wozniak, M. 28
 Wright, B. 51
 Wunderink, L. 18, 47
 Wüstenberg, T. 12

Y

Yamanaka, H. 15

Z

Zaytseva, Y. 33

FOR YOUR NOTES



Scientific Organiser

European Scientific Association
on Schizophrenia
and other Psychoses e.V. (ESAS)
www.esasnet.eu

Scientific Secretariat

Wolfgang Gaebel, Wolfgang Wölwer,
Viktoria Toeller
c/o Department of Psychiatry and Psychotherapy
Heinrich-Heine-University Düsseldorf

Congress Venue

Seminaris Science & Conference Center
The Dahlem Cube
Takustraße 39
14195 Berlin, Germany
www.seminaris.de/hotels/
seminaris-campushotel-berlin.html

Professional Conference Organiser

CPO HANSER SERVICE
Hanser & Co GmbH
PO Box 12 21
22882 Barsbüttel, Germany
Phone: +49-40-670 88 20
Fax: +49-40-670 32 83
Email: schizophrenia@cpo-hanser.de